

## UNITED STATES DISTRICT COURT

DISTRICT OF SOUTH DAKOTA

## DEFENDANT'S EXHIBIT LIST

DEANE BERG

V.

JOHNSON & JOHNSON CONSUMER  
COMPANIES, INC.,

Case Number: 4:09-CV-04179-KES

PRESIDING JUDGE Hon. Karen E. Schreier		PLAINTIFF'S ATTORNEY Gregory Eiesland/R. Allen Smith, Jr		DEFENDANT'S ATTORNEY J. Crisman Palmer / Gene M. Williams	
TRIAL DATE (S) 09/24/13 to 10/04/13		COURT REPORTER Jill Connelly/Tony Rolland		COURTROOM DEPUTY SLW	
PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1001	10/1/13	X	Rec'd	Curriculum Vitae of Philip DiSaia, M.D
	1002				Curriculum Vitae of Ernst Lengyel, M.D., Ph.D
	1003	9/30/13	X	Rec'd	Curriculum Vitae of Juan Carlos Felix, M.D.
	1004				Curriculum Vitae of John Hopkins, Ph.D.
	1005				Curriculum Vitae of Michael Huncharek, M.D.
	1006	10/1/13	X	Rec'd	Curriculum Vitae of Joshua Muscat, Ph.D.
	1007				Curriculum Vitae of Elizabeth Anderson, Ph.D.
	1008	9/30/13	X	Rec'd	Curriculum Vitae of John M. DeSesso, Ph.D.
	1009				Curriculum Vitae of Elaine Schumacher
	1010				Curriculum Vitae of Joseph R. Swider
	1011				Curriculum Vitae of David G. Hoel, Ph.D.
	1012				Curriculum Vitae of Anthony R. Scialli, M.D.
	1013				Curriculum Vitae of Christine T. Wood, Ph.D.
	1014	10/1/13	X	Refused	Expert Witness Report of Philip DiSaia, M.D., with attachments
	1015				Expert Witness Report of Ernst Lengyel, M.D., Ph.D entitled <i>An opinion in the relationship between the use of cosmetic talc and ovarian cancer relevant to the case of Ms. Deane Berg (Plaintiff) versus Johnson &amp; Johnson and Luzenac America (Defendants)</i> , with attachments
	1016				Expert Witness Report of Juan Carlos Felix, M.D., with attachments
	1017				Expert Witness Report of John Hopkins, Ph.D., with attachments
	1018				Expert Witness Report of Michael Huncharek, M.D.: <i>Scientific Opinion on the Alleged Association Between use of Cosmetic Talc on the Female Perineum and the Risk of Epithelial Ovarian Cancer: An Overview of the Scientific Evidence and its Relevance to the Case of Ms. Deane Berg</i> , with attachments
	1019				Expert Witness Report of Joshua Muscat, Ph.D.: <i>Scientific Opinion on the Alleged Association Between Use of Cosmetic Talc on the Female Perineum and the Risk of Epithelial Ovarian Cancer: An Overview of the Scientific Evidence and its Relevance to the Case of Ms. Deane Berg</i> , with attachments
	1020				Expert Witness Report of Elizabeth Anderson, Ph.D., with attachments
	1021				Expert Witness Report of John M. DeSesso, Ph.D., with attachments

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1022				Expert Witness Report of Elaine Schumacher and Joseph R. Swider entitled <i>Identification of Talc Particles in Tissue Samples</i> , with attachments
	1023				Tissue samples referenced in Report of Elaine Schumacher and Joseph R. Swider
	1024				Expert Witness Report of David G. Hoel, Ph.D., with attachments
	1025				Expert Witness Report of Anthony R. Scialli, M.D. entitled <i>Statement of Anthony R. Scialli, M.D. Re Deane Berg</i> , with attachments
	1026				Expert Witness Report of Christine T. Wood, Ph.D., with attachments
	1027				Histopathological slides for Deane Berg from Sioux Valley Hospital, Department of Pathology: 4 slides labeled SFS06-37460; 22 slides labeled SFS07-977
	1028				Bottle of Johnson's baby powder
	1029				Bottle of Shower to Shower
	1030				Johnson & Johnson Credo, available at <a href="http://www.jnj.com/sites/default/files/pdf/jnj_ourcredo_english_us_8.5x11_cmyk.pdf">http://www.jnj.com/sites/default/files/pdf/jnj_ourcredo_english_us_8.5x11_cmyk.pdf</a>
	1031				Foster, Lawrence G. <i>Robert Wood Johnson: The Gentleman Rebel</i> . Lillian Press, 1999
	1032				<i>Johnson &amp; Johnson Reflections of our Credo</i>
	1033				Foster, Lawrence G. <i>A Company That Cares. One Hundred Year Illustrated History of Johnson &amp; Johnson</i> . Johnson & Johnson, New Jersey, 1986
	1034				DiSaia, Phillip J., M.D. and William T. Creasman, M.D., <i>Clinical Gynecologic Oncology</i> . Elsevier Inc., 2007
	1035				Eccles DM, et al, <i>BRCA1 mutations in southern England</i> . BR J Cancer, 1998. 77(12): p. 2199-203
	1036				Gayther SA, et al., <i>The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes</i> . Am J Hum Genet, 1999. 65(4): p. 1021-9
	1037				Huncharek M, JF Geschwind, and B Kupelnick. <i>Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: A meta-analysis of 11,933 subjects from sixteen observational studies</i> . Anticancer Res. 203, 23(2C): p. 1955-60 (2003)
	1038				Kessler II. <i>Perspectives on the epidemiology of cervical cancer with special reference to the herpesvirus hypothesis</i> . Cancer Res, 1974. 34(5): p. 1091-110
	1039				Choi NW, et al. <i>Herpesvirus infection and cervical anaplasia: a seroepidemiological study</i> . Int J Cancer, 1977. 19(2): p. 167-71
	1040				Viikki M, et al. <i>Gynecological infections as risk determinants of subsequent cervical neoplasia</i> . Acta Oncol, 2000. 39(1): p. 71-5
	1041				Aurelian L, et al. <i>Viruses and gynecologic cancers: herpesvirus protein (ICP 10/AG-4), a cervical tumor antigen that fulfills the criteria for a marker of carcinogenicity</i> . Cancer, 1981. 48(2 Suppl): p. 455-71
	1042				Bosch FX, et al. <i>The causal relation between human papillomavirus and cervical cancer</i> . J Clin Pathol, 2002. 55(4): p. 244-65
	1043				Wright TC, Jr. and M Schiffman, <i>Adding a test for human papillomavirus DNA to cervical-cancer screening</i> . N Engl J Med, 2003. 348(6): p. 489-90
	1044				Huncharek M, Muscat J, et al. <i>Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: A meta-analysis of nine observational studies</i> . Eur J Cancer Prev, 2007; 16(5): p. 422-429
	1045				<i>Talc: Consumer Uses and Health Perspectives, A Workshop</i> . The International Society of Regulatory Toxicology and Pharmacology and the United States Food and Drug Association, January 31 – February 1, 1994
	1046	9/27/13	X	Demonstrative	Boorman GA, Seely, JC. <i>The lack of an ovary effect in lifetime talc exposure in F344/N Rats and B6C3F1 Mice</i> . Regulatory Toxicology and Pharmacology 21:242-243, 1995.
	1047				Wehner AP, et al. <i>Do particles translocate from the vagina to the oviducts and beyond?</i> Fd Chem Toxic, 23 (3) 367-372, 1985
	1048				<i>Cancer Incidence in Sweden 2007</i> , The National Board of Health & Welfare ISBN 978-91-85999-73-7, pub 25 November 2008
	1049				Ovarian Cancer–UK incidence statistics, pub by Cancer Research UK; <a href="http://www.cancerresearchuk.org">www.cancerresearchuk.org</a>
	1050				Granstrom C, et al. <i>Population attributable fractions for ovarian cancer in Swedish women by morphological type</i> . Br J Cancer, (2008) 98, 100-205
	1051				Granstrom C, et al. <i>Population attributable fractions for ovarian cancer in Swedish women by morphological type</i> . Br J Cancer, (2008) 88, 199-205

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1052				Larsson SC, Bergkvist L, Wolk A. <i>Milk and lactose intakes and ovarian cancer risk in the Swedish mammography cohort.</i> Am J Clin Nutr (2004), 80 (5), 1353-7
	1053				Toxicological Profile for Nickel, August 1995, Draft Update; Agency for Toxic Substances and Disease Registry United States Public Health Service. <a href="http://www.atsdr.cdc.gov/toxprofiles/tp15-cl.pdf">www.atsdr.cdc.gov/toxprofiles/tp15-cl.pdf</a> - United States
	1054				Anderson RA, Bryden NA, Polansky MM. <i>Dietary chromium intake: freely chosen diets, institutional diets and individual foods.</i> Biol Trace Elem Res 1992; 32:117-21
	1055				Toxicological Profile for Arsenic, August 2007; Agency for Toxic Substances and Disease Registry. U.S. Public Health Service. <a href="http://www.atsdr.cdc.gov/toxprofiles/tp2-c6.pdf">www.atsdr.cdc.gov/toxprofiles/tp2-c6.pdf</a> - United States
	1056				Godleski JJ. Report on pathology slides re Mrs. Deane Berg, March 15, 2011
	1057				Pittman TS, Elemental analysis of arsenic, nickel and chromium in Johnson's Baby Powder / Shower to Shower talc, dated January 31, 2011
	1058				Feinstein AR. 1988. <i>Scientific standards in epidemiologic studies of the menaces of daily life.</i> Science 242(4883):1257-1263.
	1059				Hill AB, 1965. <i>The environment and disease: Association or causation.</i> Proc R Sac Med 58:295-300.
	1060				Keskin N, Teksen A, Ongun EG, Ozay Y, Saygh H. (2009). <i>Does long term talc exposure have a carcinogenic effect on the female genital system of rats? Air experimental pilot study.</i> Arch Gynecol Obstet 280:925-931.
	1061				Huncharek M. (1986). <i>The biomedical and epidemiological characteristics of asbestos-related diseases: A review.</i> Yale J Biol Med 59: 435-451
	1062				Mossman BT, Gee JB. (1989). <i>Asbestos related diseases.</i> N Eng J Med 320:1721-1730.
	1063				Stanton ME, Layard M, Tegeris A et al (1981). <i>Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals.</i> J Natl Cancer Inst 67:965-975
	1064				Muscat JE, Huncharek M. (2008). <i>Perineal talc use and ovarian cancer: a critical review.</i> Eur J Cancer Prev 17:139-146.
	1065				Rohl AN, Langer AM, Selikoff I.1 et al (1975). <i>Consumer talcums and powders; mineral and chemical characterization.</i> J Toxicol Environ Health 2:255-284.
	1066				Petitti DB. <i>Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. Methods for 32 Quantitative Synthesis in Medicine.</i> 2nd ed. Oxford University Press, Oxford, UK. 2000
	1067				Rothman K. <i>Modern Epidemiology.</i> Little Brown and Co., Boston, Toronto, 1986
	1068				Huncharek M, Muscat J. (2011) <i>Perineal talc use and ovarian cancer risk: a case-study of scientific standards in environmental epidemiology.</i> Eur J Cancer Prev 20(6):501-507
	1069				Green A, Purdie D, Bain C et al. (1997). <i>Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Survey of women's health study group.</i> Int J Cancer 71:948-951
	1070				Rosenblatt KA, Mathews WA, Dailing JR et al. (1998). <i>Characteristics of women who use perineal powders.</i> Obstet Gynecol 92:753-756
	1071				Newby PK, Hu FB, Rimm EB et al.(2003). <i>Reproducibility and validity of the Diet Quality Index Revised as assessed by use of a food frequency questionnaire.</i> Am J Clin Nutr 78(5):941- 949.
	1072				Paulsen T, Keam J, Kjaerheim K et al. (2005). <i>Symptoms and referral of women with epithelial ovarian cancer.</i> Int J Gynecol Obstet 88:31-37
	1073				Goff BA, Mandel LS, Meaneon CH et al. (2004). <i>Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.</i> JAMA 291:2705-2712.
	1074				Crispens MA. (2003) <i>Borderline ovarian tumours: a review of the recent literature.</i> Current Opinion Obst Gyn 15:39-43
	1075				Jordan SJ, Green AC, Whiteman DC, Webb PM. (2007) <i>Risk factors for benign serous and mucinous epithelial ovarian tumors.</i> Obstetrics Gynecol 109(3):647-654
	1076				Muscat J, Stellman SD, Wynder E. <i>Insulation, asbestos, smoking habits and lung cancer cell type.</i> (1995). Am J Ind Med 27(2):257-269
	1077				Wehner AP. (2002). <i>Cosmetic talc should not be listed as a carcinogen: comments on NTP's deliberations to list talc as a carcinogen.</i> Regulat Toxicol Pharmacol 36:40-50.
	1078				Sjosten AC, Ellis H, Edelstam GA et al. (2004). <i>Retrograde migration of glove powder in the human female genital tract.</i> Hum Reprod 19:991-995.
	1079				Henderson WJ, Joskin CA, Turnbull AC, Griffiths K (1979). <i>Talc and carcinoma of the ovary and cervix.</i> J Obstet Gynecol Br Commonwealth 78:266-272.
	1080				Henderson WJ, Hamilton TC, Griffiths K (1979). <i>Talc in normal and malignant ovarian tissue.</i> Lancet 1:499
	1081				Heller DS, Westhoff C, Gordon RE et al. (1996) <i>The relationship between perineal cosmetic talc usage and ovarian talc particle burden.</i> Am J Obstet Gynecol 174:1507-1510

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1082				Heller DS, Gordon RE, Westhoff C, Gerber S. (1996) <i>Asbestos exposure and ovarian fiber burden</i> . Am J Ind Med 29:435-439.
	1083				Cramer DW, Titus-Ernstoff L, McKolanis JR et al.(2005) <i>Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer</i> . Cancer Epidemiol Biomarkers Prev 14(5):1125-1131
	1084				Cramer DW. (2005) <i>Talc and anti-MUC1 antibodies</i> . Cancer Epidemiol Biomarker Prev. 14:2679
	1085				Goodman MT, Howe HL, Tung KH et al. <i>Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997</i> . Cancer 97:2676-2685.
	1086				Bonovas S, Filioussi K, Sitaras NM.(2005) <i>Do non-steroidal anti-inflammatory drugs affect the risk of developing ovarian cancer. A meta-analysis</i> . Br J Clin Pharmacol 60(2):194-203.
	1087				Gabridge MG, Denunzio AL, Legator MS (1969). <i>Microbial mutagenicity of streptozotocin in animal mediated assays</i> . Nature 221:68-70
	1088				Hildick-Smith G.(1976). <i>The biology of talc</i> . Br J Indust Med 33:217-229
	1089				Grigorev ZE (1963). <i>Irritant action of spodumen concentrate dust on the integument of experimental rabbits</i> . Vestnik Dermatologii I Venerologii 8:13-15.
	1090				Bluemel G, Piza F, et al. (1962) <i>Animal experiments on tissue reaction to the intraperitoneal use of starch and talcum powders</i> . Wiener Klinische Wochenschrift 74:12-13
	1091				Pott R, Friedrichs KH. (1972). <i>Tumors in rats following i.p. injection of fiberform dusts</i> . Naturwissenschaften 59:318-324
	1092				Smith WE, Miller I, Elsasser RE et al. (1965) <i>Tests for the carcinogenicity of asbestos</i> . Annals of the NY Academy of Sciences 132:456-488
	1093				Gross P, DeTreville RTP, Cralley LJ. (1970). <i>Studies on the carcinogenic effects of asbestos dust</i> . In: Pneumoconiosis: Proceedings of an International Conference, Johannesburg, 1969, ed. H.A. Shapiro, pp.220-224. Oxford University Press, London.
	1094				Wagner JC, Berry G, Cook J et al. (1975) <i>Animal experiments with talc</i> . Inhaled Part 4(2):647-654.
	1095				Lord GH. (1978). <i>The biological effects of talc in the experimental animal: A literature review</i> . Food Cosmet Toxicol 16(1):51-57.
	1096				Shaw P, Agarwal R. (2004) <i>Pleurodesis for malignant pleural effusions</i> . Cochrane Database for Systematic Reviews. 1:CD002916. DOI: 10.1002/14651858. CD009216.pub2. 34
	1097				Rubino GF, Scansetti G, Piolatto G, Romano CA. (1976) <i>Mortality study of talc miners and millers</i> . J Occup Med 18(3):186-193.
	1098				Wergeland E, Andersen A, Baerheim A. (1990). <i>Morbidity and mortality in talc exposed workers</i> . Am J Ind Med 17:505-513.
	1099				Ramanakumar AV, Parent ME, Latreille B et al.(2008) <i>Risk of lung cancer following exposure to carbon black, titanium dioxide and talc: results from two case-control studies in Montreal</i> . 122(1):183-189
	1100				Honma N, Hirastuka T, Kozawa E, Watanabe A, Saijo K et al. (1963) <i>Clinical aspects of spontaneous pneumothorax. Origin and results of treatment in 70 cases</i> . Chiryo 45:2169-2174
	1101				Lange P, Mortensen J, Groth S. (1988). <i>Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poundrage or simple drainage</i> . Thorax 43:559-561
	1102				Anonymous (1979). Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit. <i>A survey of the long-term effects of talc and kaolin pleurodesis</i> . Br J Dis Chest 73:285-288
	1103				Fairfield KM, Hunter DJ, Colditz GA et al. (2004). <i>A prospective study of dietary lactose and ovarian cancer</i> . Int J Cancer 11:271-277
	1104				Larsson SC, Bergkvist L, Wolk A. (2004). <i>Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort</i> . 80:1353-1357.
	1105	9/25/13	X	Demonstrative	Harlow BL, Cramer DW et al. (1995) <i>Self-reported use of anti-depressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two case-control studies</i> . Cancer Causes Control 6:130-134.
	1106				Whittemore A, Harris R et al. (1992) <i>Characteristics relating to ovarian cancer risk. Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women</i> . Collaborative Ovarian Cancer Group. Am J Epid 136(10):1184-1203
	1107				Danforth KN, Tworoger SS, Hecht JL et al. (2007) <i>Breastfeeding and risk of epithelial ovarian cancer in two prospective cohort studies</i> . Cancer Causes Control 18(5):517-527.
	1108	9/25/13	X	Demonstrative	Gates MA, Rosner BA, Hecht JL et al. (2009). <i>Risk factors for epithelial ovarian cancer by histological subtype</i> . Am J Epidemiol 171(1):45-53.
	1109				Huncharek M. (1992). <i>Changing risk groups for malignant mesothelioma</i> . Cancer 69(1):2704-2711.

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1110				Dement JM, Ringenk K, Welch LS et al.(2009). <i>Mortality of older construction and craft workers employed at Department of Energy nuclear sites.</i> Am J Ind Med 52(9):671-682.
	1111				Olsen NJ, Franklin PJ, Reid A et al.(2011). <i>Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation.</i> Med J Aust 195(5):271-271.
	1112				Goldberg M, Luce D. <i>The health impact of non-occupational exposure to asbestos: what do we know?</i> Eur J Cancer Prev (in press, currently electronically published).
	1113				Huncharek M, Capotorto JV, Muscat J. (1989). <i>Domestic asbestos exposure, lung fiber burden and pleural mesothelioma in a housewife.</i> Br J Ind Med 46:354-355.
	1114				Camargo MC, Stayner LT, Straif K et al. (2011). <i>Occupational exposure to asbestos and ovarian cancer: a meta-analysis.</i> Environ Health Perspectives 119:1211-1217.
	1115				Straif K, Benbrahim-Talla L, Baan R et al. (2009). <i>A review of human carcinogens-Part C: metals, arsenic, dusts and fibers.</i> Lancet Oncology 10:453-454.
	1116				Wignall BK, Fox AJ. (1982). <i>Mortality of female gas mask assemblers.</i> Br J Ind Med 39(1):34-38. Michael Huncharek MD, MPH Meta-Analysis Research Group 36
	1117				American Cancer Society. <i>Cancer Facts and Figures 2004.</i> Atlanta, GA: American Cancer Society, 2004
	1118				Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. <i>Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.</i> BMJ 1993; 306:1030-4
	1119				Partridge EE, Barnes MN. <i>Epithelial ovarian cancer: prevention, diagnosis and treatment.</i> CA Cancer J Clin 1999; 49: 297-316
	1120				NIH Consensus Development Panel on Ovarian Cancer. <i>Ovarian cancer: screening, treatment and follow-up.</i> JAMA 1995; 273:491-7
	1121				Fathalla MF. <i>'Incessant ovulation' – a factor in ovarian neoplasia?</i> Lancet 1971; 2:163
	1122				Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. <i>'incessant ovulation' and ovarian cancer.</i> Lancet 1979; 2:170-3
	1123				Cramer DW, Welch WR. <i>Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis.</i> J Natl Cancer Inst 1983; 71:717-21
	1124				Ness RB, Cottreau C. <i>Possible role of ovarian epithelial inflammation in ovarian cancer.</i> J Natl Cancer Inst 1999; 91:1459-67
	1125				Bosetti C, Gallus S, La Vecchia C. <i>Aspirin and cancer risk: an update to 2001.</i> Eur J Cancer Prev 2002; 11:535-42
	1126				Baron JA. <i>Epidemiology of non-steroidal anti-inflammatory drugs and cancer.</i> Prog Exp Tumor Res 2003; 37:1-24
	1127				Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. <i>Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.</i> BMC Cancer 2003; 3:28
	1128				Berek JS. 2009 <i>Lymph node-positive stage IIIC ovarian cancer - A separate entity?</i> Int J Gynecol Cancer 19:18-20
	1129				Cibula D, Widschwendter M, Majek O, Dusek L. 2011 <i>Tubal ligation and the risk of ovarian cancer: Review and meta-analysis.</i> Human Reproduction Update 17:55-67
	1130				Grimes DA, Schultz KF. 2002 <i>Bias and causal associations in observational research.</i> Lancet 359:248-252
	1131	10/2/13	X	Demonstrative	Cramer D W; Welch W R; Scully R E; Wojciechowski C A; 1982. <i>Ovarian cancer and talc.</i> Cancer 50:372-376
	1132				Harlow BL, Cramer DW, Bell DA, Welch WR. 1992. <i>Perineal exposure to talc and ovarian cancer risk.</i> Obstet Gynecol 80(1):19-26
	1133	10/1/13	X	Demonstrative	Wong C, Hempling RE, Piver MS, Natarajan N, Mettlin C. 1999 <i>Perineal talc exposure and subsequent epithelial ovarian cancer: A case-control study.</i> Obstet Gynecol 93:372-376
	1134	10/1/13	X	Demonstrative	Rosenblatt KA, Weiss NS, Cushing-Haugen KL, Wicklund KG, Rossing MA. <i>Genital powder exposure and the risk of epithelial ovarian cancer.</i> Cancer Causes Control (2011) 22:737-742
	1135				Langseth H, Hankinson SE, Siemiatycki J, Weiderpass E. 2008 <i>Perineal use of talc and risk of ovarian cancer.</i> J Epidemiol Community Health 62:358-360
	1136	9/25/13	X	Demonstrative	Gertig DW, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, Hankinson SE. 2000 <i>Prospective study of talc use and ovarian cancer.</i> J Natl Cancer Inst 92:249-252
	1137				Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Coglianò V. 2006 <i>Carcinogenicity of carbon black, titanium oxide, and talc.</i> Lancet Oncology 7:295-296
	1138				Taubes G. 1995 <i>Epidemiology faces its limits.</i> Science 269:164-169
	1139				Doll R, Peto R, Wheatley K, Gray R, Sutherland I. 1994. <i>Mortality in relation to smoking: 40 years observations on male British doctors.</i> British Medical Journal 309:901-911



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1140				Hanahan D, Weinberg RA. 2000. <i>The hallmarks of cancer</i> . Cell 100:57-70
	1141				Hanahan D, Weinberg RA. 2011. <i>Hallmarks of cancer: The next generation</i> . Cell 144:646-674
	1142				The Cancer Atlas Network. 2011. <i>Integrated genomic analyses of ovarian carcinoma</i> . Nature 474(7353):609-615
	1143				Ahmet AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, DeFazio A, Bowtell D, Brenton JD. 2010. <i>Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary</i> . J Pathology 221:49-56
	1144	9/27/13	X	Demonstrative	Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. 1999. <i>Talc induces apoptosis in human malignant mesothelioma cells in vitro</i> . American Journal of Critical Care Medicine 161:595-600
	1145	9/27/13	X	Demonstrative	Lee P, Sun L, Lim CK, Aw SE, Colt HG. 2011. <i>Selective apoptosis of lung cancer cells with talc</i> . European Respiratory Journal 35:450-452
	1146				Keskin N, Teksen YA, Ongun EG, Ozay Y, Saygh H. 2009 <i>Does long-term talc exposure have a carcinogenic effect on the female genital system of rats? An experimental pilot study</i> . Arch Gynecol Obstetrics 280:925-631
	1147				Nasreen N, Mohammed KA, Brown.S, Su Y, Sriram PS, Moudgill B, Loddenkemper R, Antony VB. 2007. <i>Talc mediates angiostasis in malignant pleural effusions via endostatin induction</i> . European Respiratory Journal 2007:761-769
	1148				Viskum K, Lange P, Mortensen J. 1989 <i>Long term sequelae after talc pleurodesis for spontaneous pneumothorax</i> . Pneumologie 43:105-106
	1149				Gyorik S, Erni S, Studler U, Hodek-Wuerz R, Tamm M, Chhajed PN. 2007. <i>Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax</i> . European Respiratory Journal 29:757-760
	1150				Jonckheere N, Van Seuning I. 2010. <i>The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers</i> . Biochimie 92:1-11
	1151				Feng H, Ghazizadeh M, Konishi H, Araki T. 2002. <i>Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas</i> . Jpn J Clinical Oncology 32:525-529
	1152				Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, McGuckin MA. 1997. <i>Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours</i> . J Pathology 183:311-317
	1153				Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. 2005. <i>Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer</i> . Cancer Epidemiol Biomarkers Prev. 14:1125-2679
	1154				Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW. 2010. <i>Anti-MUC1 antibodies and ovarian cancer risk: Prospective data from the nurses' health studies</i> . Cancer Epidemiol Biomarkers Prev. 19(6):1595-1601
	1155				Vlad AM, Diaconu I, Gantt KR. 2006. <i>MUC1 in endometriosis and ovarian cancer</i> . Immunologic Research 36:229-236
	1156				Hermesen BBJ, Verheijen RHM, Menko FH, Gille JJP, Van Uffelen K, Blakenstein MA, Meijer S, Van Diest PJ, Kenemans P, Von Mensdorff-Pouilly S. 2007 <i>Humoral immune responses to MUC1 women with a BRCA1 or BRCA2 mutation</i> . European Journal of Cancer 43:1556-1563
	1157				Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. 1998. <i>Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women</i> . Cancer Immunology and Immunotherapy 46:245-252
	1158				Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Eriandsson F, Acton G, Pegram M. 2011. <i>Randomized phase II trial of letrozole plus anti-MUC1 antibody ASI402 in hormone receptor-positive locally advanced or metastatic breast cancer</i> . Clin Cancer Res 17:6822-6830
	1159				Verheijen RHM, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV. 2006. <i>Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission</i> . J Clin Oncol 24:571-577
	1160				Beatson RE, Taylor-Papadimitriou J, Burchell JM. 2010. <i>MUC1 immunotherapy</i> . Immunotherapy 2:305-327
	1161				Hill AB. 1965. <i>The environment and disease: Association or causation?</i> Proc R Soc Med 58:295-300
	1162	10/1/13	X	Demonstrative	Muscat J.E., Barish M. Epidemiology of talc exposure and ovarian cancer. A critical appraisal. Comments on Toxicology 1998; 6:327-335.
	1163	10/1/13	X	Demonstrative	Muscat JE, Wynder EL. Letter to the Editor at American Journal of Epidemiology Re: Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 146:786?

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1164	10/1/13	X	Demonstrative	Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM. <i>Ovarian Cancer Risk Factors in African-American and White Women</i> . Am J Epidemiol. Sep 1 2009; 170(5):598-606
	1165	10/1/13	X	Demonstrative	Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. <i>Markers of inflammation and risk of ovarian cancer in Los Angeles County</i> . Int J Cancer. Mar 15 2009; 124(6):1409-1415
	1166				Muscat J, Huncharek M, Cramer DW. <i>Talc and anti-MUC1 antibodies</i> . Cancer Epidemiol Biomarkers Prev. Nov 2005; 14(11 Pt 1):2679; author reply 2680.
	1167				Karageorgi S, Gates MA, Hankinson SE, De Vivo I. <i>Perineal use of talcum powder and endometrial cancer risk</i> . Cancer Epidemiol Biomarkers Prev. May 2010; 19(5):1269-1275
	1168				Neill AS, Nagle CM, Spurdle AB, Webb PM. <i>Use of talcum powder and endometrial cancer risk</i> . Cancer Causes Control. Jan 14 2012
	1169				Serraino D, Piselli P, Busnach G, et al. <i>Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe</i> . Eur J Cancer. Sep 2007; 43(14):2117-2123
	1170				Cook TD, Campbell Donald T. <i>Quasi-Experimentation: Design and analysis issues for field settings</i> . Boston: Houghton Mifflin Co.; 1979
	1171				Rothman K, Greenland, S. <i>Modern Epidemiology</i> . Second Edition ed: Lippincott, Williams and Wilkins; 1998
	1172	10/1/13	X	Demonstrative	Zota AR, Aschengrau A, Rudel RA, Brody JG. <i>Self-reported chemicals exposure, beliefs about disease causation, and risk of breast cancer in the Cape Cod Breast Cancer and Environment Study: a case-control study</i> . Environ Health. 2010; 9:40
	1173				Cramer D W; Welch W R; Scully R E; Wojciechowski C A; <i>Ovarian cancer and talc: a case-control study</i> . Cancer. July 15 1982; 50(2):372-376
	1174				Harlow BL, Cramer DW, Bell DA, Welch WR. <i>Perineal exposure to talc and ovarian cancer risk</i> . Obstet Gynecol. July 1992; 80(1):19-26
	1175				Rothman KJ. <i>Occam's razor pares the choice among statistical models</i> . Am J Epidemiol. Nov 1978; 108(5 ):347-349
	1176				Colditz GA, Miller JN, Mosteller F. <i>How study design affects outcomes in comparisons of therapy</i> . I: Medical. Stat Med. Apr 1989; 8(4):441-454
	1177				Ioannidis JP, Haidich AB, Pappa M, et al. <i>Comparison of evidence of treatment effects in randomized and nonrandomized studies</i> . JAMA. Aug 15 2001; 286(7):821-830
	1178				Shikata S, Nakayama T, Noguchi Y, Taji Y, Yamagishi H. <i>Comparison of effects in randomized controlled trials with observational studies in digestive surgery</i> . Ann Surg. Nov 2006; 244(5):668-676
	1179				Benson K, Hartz AJ. <i>A comparison of observational studies and randomized, controlled trials</i> . N Engl J Med. Jun 22 2000; 342(25):1878-1886
	1180				Buiatti E. <i>Evaluation of human trial design</i> . IARC Sci Publ. 1996 (139):261-269
	1181				Greenwald P. <i>Beta-carotene and lung cancer: a lesson for future chemoprevention investigations?</i> J Natl Cancer Inst. Jan 1 2003; 95(1):E1
	1182				<i>The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers</i> . The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. Apr 14 1994; 330(15):1029-1035
	1183				Omenn GS, Goodman GE, Thornquist MD, et al. <i>Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease</i> . N Engl J Med. May 2 1996; 334(18):1150-1155
	1184				Hennekens CH, Buring JE, Manson JE, et al. <i>Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease</i> . N Engl J Med. May 2 1996; 334(18):1145-1149
	1185				Lippman SM, Klein EA, Goodman PJ, et al. <i>Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</i> . JAMA. Jan 7 2009; 301(1):39-51.
	1186				Duffield-Lillico AJ, Begg CB. <i>Reflections on the landmark studies of beta-carotene supplementation</i> . J Natl Cancer Inst. Dec 1 2004;96(23): 1729-1731
	1187				Harris RE, Beebe-Donk J, Doss H, Burr Doss D. <i>Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)</i> . Oncol Rep. Apr 2005; 13(4):559-583
	1188				Cooper K, Squires H, Carroll C, et al. <i>Chemoprevention of colorectal cancer: systematic review and economic evaluation</i> . Health Technol Assess. Jun 2010; 14(32): 1-206
	1189				Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. <i>Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials</i> . Lancet. Jan 1 2011; 377(9759):31-41
	1190				Takkouche B, Regueira-Mendez C, Etminan M. <i>Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis</i> . J Natl Cancer Inst. Oct 15 2008; 100(20):1439 - 1447

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1191				Cook NR, Lee IM, Gaziano JM, et al. <i>Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.</i> JAMA. Jul 6 2005; 294(1):47-55
	1192				Rosenblatt KA, Weiss NS, Cushing-Haugen KL, Wicklund KG, Rossing MA. <i>Genital powder exposure and the risk of epithelial ovarian cancer.</i> Cancer Causes Control. May 2011; 22(5):737-742
	1193				Lubin JH, Caporaso NE. <i>Cigarette smoking and lung cancer: modeling total exposure and intensity.</i> Cancer Epidemiol Biomarkers Prev. Mar 2006; 15(3):517-523
	1194				Longo DL, Young RC. <i>Cosmetic talc and ovarian cancer.</i> Lancet. Nov 10 1979; 2(8150):1011-1012
	1195				Huncharek M, Muscat J, Onitilo A, Kupelnick B. <i>Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies.</i> Eur J Cancer Prev. Oct 2007; 16(5):422-429
	1196				Hartge P, Stewart P. <i>Occupation and ovarian cancer: a case-control study in the Washington, DC, metropolitan area, 1978-1981.</i> J Occup Med. Aug 1994; 36(8):924-927
	1197				Bethune N. <i>Pleural poudrage: a new technique for the deliberate production of pleural adhesions as a preliminary to lobectomy.</i> J Thorac Surg. 1935; 4:251-261
	1198				Tribble CG, Selden RF, Rodgers BM. <i>Talc poudrage in the treatment of spontaneous pneumothoraces in patients with cystic fibrosis.</i> Ann Surg. Dec 1986; 204(6):677-680
	1199				Gyorik S, Erni S, Studler U, Hodek-Wuerz R, Tamm M, Chhajed PN. <i>Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax.</i> Eur Respir J. Apr 2007; 29(4):757-760
	1200				Honma N, Hiratsuka T, Kozawa E, Watanabe A, Saijo K, Shimizu K [Clinical Aspects of Spontaneous Pneumothorax. Origin and Results of Treatment in 70 Cases]. Chiryō. 1963; 45:2169-2174
	1201				Lange P, Mortensen J, Groth S. <i>Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage.</i> Thorax. Jul 1988; 43(7):559-561
	1202	10/1/13	X	Demonstrative	Chapell A, Johnson A, Charles JWJ, et al. <i>A survey of the long-term effects of talc and kaolin pleurodesis. Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit.</i> British Journal of Diseases of the Chest. Jul 1979; 73(3):285-288
	1203				Viskum K, Lange P, Mortensen J. <i>Long term sequelae after talc pleurodesis for spontaneous pneumothorax.</i> Pneumologie. Feb 1989; 43(2):105-106
	1204				Muscat JE, Wynder EL. <i>Cigarette smoking, asbestos exposure, and malignant mesothelioma.</i> Cancer Res. May 1 1991; 51(9):2263-2267
	1205				Melton LJ, 3rd, Hepper NG, Offord KP. <i>Incidence of spontaneous pneumothorax in Olmsted County, Minnesota: 1950 to 1974.</i> Am Rev Respir Dis. Dec 1979; 120(6):1379-1382
	1206				Wakai AP. <i>Spontaneous pneumothorax.</i> Clin Evid (Online). 2011; 2011.
	1207				Gray H, Lewis WH. <i>Anatomy of the human body.</i> 20th ed. Philadelphia and New York,: Lea & Febiger; 1918
	1208				Wilson KM, Mucci LA, Cho E, Hunter DJ, Chen WY, Willett WC. <i>Dietary acrylamide intake and risk of premenopausal breast cancer.</i> Am J Epidemiol. Apr 15 2009; 169(8):954-961
	1209				Wilson KM, Balter K, Adami HO, et al. <i>Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study.</i> Int J Cancer. May 15 2009; 124(10):2384-2390
	1210				Wilson KM, Vesper HW, Tocco P, et al. <i>Validation of a food frequency questionnaire measurement of dietary acrylamide intake using hemoglobin adducts of acrylamide and glycidamide.</i> Cancer Causes Control. Apr 2009; 20(3):269-278
	1211				Marks GC, Hughes MC, van der Pols JC. <i>Relative validity of food intake estimates using a food frequency questionnaire is associated with sex, age, and other personal characteristics.</i> J Nutr. Feb 2006; 136(2):459-465
	1212				Maruti SS, Feskanich D, Colditz GA, et al. <i>Adult recall of adolescent diet: reproducibility and comparison with maternal reporting.</i> Am J Epidemiol. Jan 1 2005; 161(1):89-97
	1213				Frazier AL, Willett WC, Colditz GA. <i>Reproducibility of recall of adolescent diet: Nurses' Health Study (United States).</i> Cancer Causes Control. Nov 1995; 6(6):499-506
	1214				Rosner B, Gore R. <i>Measurement error correction in nutritional epidemiology based on individual foods, with application to the relation of diet to breast cancer.</i> Am J Epidemiol. Nov 1 2001; 154(9):827-835
	1215				Giovannucci E, Colditz G, Stampfer MJ, et al. <i>The assessment of alcohol consumption by a simple self-administered questionnaire.</i> Am J Epidemiol. Apr 15 1991; 133(8):810-817
	1216				Salvini S, Hunter DJ, Sampson L, et al. <i>Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption.</i> Int J Epidemiol. Dec 1989; 18(4):858-867



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1217				Robinson WR, Stevens J, Gammon MD, John EM. <i>Obesity before age 30 years and risk of advanced prostate cancer</i> . Am J Epidemiol. Jun 15 2005;161(12):1107-1114
	1218				Keshtkar AA, Semnani S, Pourshams A, et al. <i>Pictogram use was validated for estimating individual's body mass index</i> . J Clin Epidemiol. Jun 2010; 63(6):655-659
	1219	10/2/13	X	Demonstrative	Cramer DW, Liberman RF, Titus-Ernstoff L, et al. <i>Genital talc exposure and risk of ovarian cancer</i> . Int J Cancer. May 5 1999; 81(3):351-356
	1220				Wagner JC, Berry G, Cooke TJ, Hill RJ, Pooley FD, Skidmore JW. <i>Animal experiments with talc. Inhaled Part</i> . Sep 1975; 4 Pt 2:647-654
	1221	9/27/13	X	Demonstrative	Boorman GA, Seely JC. <i>The lack of an ovarian effect of lifetime talc exposure in F344/N rats and B6C3F1 mice</i> . Regul Toxicol Pharmacol. Apr 1995; 21(2):242-243
	1222				Hamilton TC, Fox H, Buckley CH, Henderson WJ, Griffiths K. <i>Effects of talc on the rat ovary</i> . Br J Exp Pathol. Feb 1984; 65(1): 101-106
	1223				<i>NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)</i> . Natl Toxicol Program Tech Rep Ser. Sep 1993; 421:1-287
	1224				Egli GE, Newton M. <i>The transport of carbon particles in the human female reproductive tract. Fertility and sterility</i> . Mar-Apr 1961; 12:151-155
	1225				Venter PF, Iturralde M. <i>Migration of a particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries</i> . S Afr Med J. Jun 2 1979; 55(23):917-919
	1226	9/27/13	X	Demonstrative	Phillips JC, Young PJ, Hardy K, Gangolli SD. <i>Studies on the absorption and disposition of 3H-labelled talc in the rat, mouse, guinea-pig and rabbit</i> . Food Cosmet Toxicol. Apr 1978; 16(2):161-163
	1227	9/27/13	X	Demonstrative	Wehner AP, Weller RE, Lepel EA. <i>On talc translocation from the vagina to the oviducts and beyond</i> . Food and Chemical Toxicology: an international journal published for the British Industrial Biological Research Association. Apr 1986; 24(4):329-338
	1228				Wehner AP, Hall AS, Weller RE, Lepel EA, Schirmer RE. <i>Do particles translocate from the vagina to the oviducts and beyond?</i> Food and chemical toxicology: an international journal published for the British Industrial biological Research Association. Mar 1985; 23(3):367-372
	1229				Stellman SD, Djordjevic MV, Muscat JE, et al. <i>Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York</i> . Cancer Epidemiol Biomarkers Prev. Jun 1998; 7(6):489-496
	1230				Stellman SD, Djordjevic MV, Britton JA, et al. <i>Breast cancer risk in relation to adipose concentrations of organochlorine pesticides and polychlorinated biphenyls in Long Island, New York</i> . Cancer Epidemiol Biomarkers Prev. Nov 2000; 9(11):1241-1249
	1231				Langseth H, Johansen BV, Nesland JM, Kjaerheim K. <i>Asbestos fibers in ovarian tissue from Norwegian pulp and paper workers</i> . Int J Gynecol Cancer. Jan-Feb 2007;17(1):44-49
	1232				Roggli V. <i>Experimental models of asbestos-related diseases</i> . Boston: Little Brown & Company; 1992
	1233				Xu A, Huang X, Lien YC, Bao L, Yu Z, Hei TK. <i>Genotoxic mechanisms of asbestos fibers: role of extranuclear targets</i> . Chemical research in toxicology. May 2007; 20(5):724-733
	1234				Friedrichs KH, Brockmann M, Fischer M, Wick G. <i>Electron microscopy analysis of mineral fibers in human lung tissue</i> . American journal of industrial medicine. 1992; 22(1):49-58
	1235				Heller DS, Gordon RE, Westhoff C, Gerber S. <i>Asbestos exposure and ovarian fiber burden</i> . Am J Ind Med. May 1996; 29(5):435-439
	1236				Henderson WJ, Hamilton TC, Griffiths K. <i>Talc in normal and malignant ovarian tissue</i> . Lancet. Mar 3 1979; 1(8114):499
	1237				Henderson WJ, Joslin CA, Turnbull AC, Griffiths K. <i>Talc and carcinoma of the ovary and cervix</i> . J Obstet Gynaecol Br Commonw. Mar 1971; 78(3):266-272
	1238				Heller DS, Westhoff C, Gordon RE, Katz N. <i>The Relationship Between Perineal Cosmetic Talc Usage and Ovarian Talc Particle Burden</i> . Am J Obstet Gynecol. May 1996; 174(5): 1507-1510
	1239				Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L. <i>Pelvic inflammatory disease and risk of ovarian cancer</i> . Cancer Epidemiology, Biomarkers & Prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 1996; 5(8):667 -669
	1240				Risch HA, Howe GR. <i>Pelvic inflammatory disease and the risk of epithelial ovarian cancer</i> . Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Jul-Aug 1995; 4(5):447-451
	1241				Shu XO, Brinton LA, Gao YT, Yuan JM. <i>Population-based case-control study of ovarian cancer in Shanghai</i> . Cancer research. Jul 1 1989; 49(13):3670-3674
	1242				Lin HW, Tu YY, Lin SY, et al. <i>Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study</i> . Lancet Oncol. Sep 2011; 12(9):900-904

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1243	10/1/13	X	Demonstrative	Merritt MA, Green AC, Nagle CM, Webb PM. <i>Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.</i> Int J Cancer. Jan 1 2008; 122(1):170-176
	1244				Munksgaard PS, Blaakaer J. <i>The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data.</i> Gynecol Oncol. Oct 2011; 123(1):157-163
	1245				Munksgaard PS, Blaakaer J. <i>The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations.</i> Gynecol Oncol. Jan 2012; 124(1):164-169
	1246				Bonovas S, Filioussi K, Sitaras NM. <i>Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.</i> Br J Clin Pharmacol. Aug 2005; 60(2): 194-203
	1247				Wynder EL, Dodo H, Barber HR. <i>Epidemiology of cancer of the ovary.</i> Cancer. Feb 1969; 23(2):352-370
	1248				West RO. <i>Epidemiologic study of malignancies of the ovaries.</i> Cancer. Jul 1966; 19(7): 1001-1007
	1249				Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. <i>A case control study of carcinoma of the ovary.</i> British journal of preventive & social medicine. Sep 1977; 31(3):148-153
	1250				Menczer J, Modan M, Ranon L, Golan A. <i>Possible role of mumps virus in the etiology of ovarian cancer.</i> Cancer. Apr 1979; 43(4): 1375-1379
	1251				Cramer DW, Welch WR, Cassells S, Scully RE. <i>Mumps, menarche, menopause, and ovarian cancer.</i> Am J Obstet Gynecol. Sept 1 1983; 147(1):1-6
	1252				Schiffman MH, Hartge P, Leshner LP, McGowan L. <i>Mumps and postmenopausal ovarian cancer.</i> Am J Obstet Gynecol. May 1 1985; 152(1):116-118
	1253				Golan A, Joosting AC, Orchard ME. <i>Mumps virus and ovarian cancer.</i> S Afr Med J. Jul 7 1979; 56(1):18-20
	1254				Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA. <i>Risk factors for epithelial ovarian cancer in Beijing, China.</i> International Journal of Epidemiology. Feb 1992; 21(1):23-29
	1255				Lambe M, Johansson AL, Altman D, Eloranta S. <i>Mastitis and the risk of breast cancer.</i> Epidemiology. Sep 2009; 20(5):747-751
	1256				Bafna S, Kaur S, Batra SK. <i>Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.</i> Oncogene. May 20 2010; 29(20):2893-2904
	1257				Gendler SJ. <i>MUC1, the renaissance molecule.</i> J Mammary Gland Biol Neoplasia. Jul 2001; 6(3):339-353
	1258				Barratt-Boyes SM. <i>Making the most of mucin: a novel target for tumor immunotherapy.</i> Cancer Immunol Immunother. Nov 1996; 43(3): 142-151
	1259				Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. <i>A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.</i> International journal of cancer. Journal international du cancer. Oct 15 1989; 44(4):691-696
	1260				Chauhan SC, Kumar D, Jaggi M. <i>Mucins in ovarian cancer diagnosis and therapy.</i> J Ovarian Res. 2009; 2:21
	1261				Erbagci AB, Yilmaz N, Kutlar I. <i>Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women.</i> Dis Markers. Dec 1999; 15(4):259-267
	1262				Hey NA, Graham RA, Seif MW, Aplin JD. <i>The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase.</i> J Clin Endocrinol Metab. Feb 1994;78(2):337-342
	1263				Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. 2007. <i>Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.</i> Cancer Epidemiology, Biomarkers & Prevention 16(1):30-35
	1264				Lee P, Sun L, Lim CK, Aw SE, Colt HG. <i>Selective apoptosis of lung cancer cells with talc.</i> The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. Feb 2010; 35(2):450-452
	1265				Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. <i>Talc induces apoptosis in human malignant mesothelioma cells in vitro.</i> Am J Respir Crit Care Med. Feb 2000; 161(2 Pt 1):595-600
	1266				Muscat J, Huncharek M, Cramer DW. 2005. <i>Talc and anti-MUC1 antibodies.</i> Cancer Epidemiology, Biomarkers & Prevention 14(11):2679. Comment on: Cancer Epidemiology, Biomarkers & Prevention 14:1125-1131 with author's reply. November 2005.
	1267				Muscat J, Huncharek M, Cramer DW. 2005. <i>Talc and anti-MUC1 antibodies.</i> Cancer Epidemiology, Biomarkers & Prevention 14(11):2679. Comment on Cancer Epidemiol Biomarkers Prev 14(5):1125-1131. November 2005.

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1268				Karageorgi S, Gates MA, Hankinson SE, De Vivo I. <i>Perineal use of talcum powder and endometrial cancer risk</i> . Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2010; 19(5): 1269-1275.
	1269				Cramer DW, Titus-Ernstoff L, McKolanis JR, et al. <i>Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer</i> . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2005; 14(5):1125- 1131.
	1270				Clendenen TV, Koenig KL, Arslan AA, et al. <i>Factors associated with inflammation markers, a cross-sectional analysis</i> . Cytokine. Dec 2011; 56(3):769-778
	1271				Carbon black, titanium dioxide, and talc/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: International Agency for Research on Cancer; 2010
	1272				Freedman ML, Monteiro AN, Gayther SA, et al. <i>Principles for the post-GWAS functional characterization of cancer risk loci</i> . Nat Genet. Jun 2011; 43(6):513- 518
	1273				Muscat JE, Huncharek MS. <i>Causation and disease: biomedical science in toxic tort litigation</i> . J Occup Med. Dec 1989; 31(12):997-1002
	1274				<i>Adult use of Baby Powder, Body Powder, Dusting Powder and Athletic Powder</i> . A report by de Kadt Marketing and Research, Inc.
	1275				ACS. 2008. Mission Statements
	1276				ACS. 2010. Talcum powder and cancer. Available at: <a href="http://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/AtHome/talcum-powder-and-cancer">http://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/AtHome/talcum-powder-and-cancer</a> . American Cancer Society
	1277				ACS. 2011. Ovarian cancer. Accessed September 28, 2011. Available at <a href="http://www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf">http://www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf</a> . American Cancer Society
	1278				Berek JS, GM Thomas, and RF Ozols. 2000. Ovarian cancer. In: RC Bast, DW Kufe, RE Pollock, RR Weichselbaum, JF Holland, and E Frei (Eds.). Holland-Frei Cancer Medicine
	1279				Breslow NE and Day NE. 1980. <i>Statistical methods in cancer research, Vol. 1: The analysis of case control studies</i> . IARC Scientific Publication No. 32. World Health Organization, International Agency for Research on Cancer, Lyon.
	1280				Carr, CJ. 1995. <i>Talc: Consumer uses and health perspectives</i> . Reg. Tox. Pharm. 21:211-215
	1281				Cramer DW, RF Liberman, L Titus-Ernstoff, WR Welch, ER Greenberg, JA Baron and BL Harlow. 1999. <i>Genital talc exposure and risk of ovarian cancer</i> . Int J Cancer. 81:351-356
	1282				Cramer DW, L Titus-Ernstoff, JR McKolanis, WR Welch, AF Vitonis, RS Berkowitz, OJ Finn. 2005 <i>Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer</i> . Cancer Epidemiol. Biomarkers Prev. 14(5):1125-1131
	1283				Cramer, DW. 2011. <i>Genital talc use and ovarian cancer: Influence of histologic type and menopausal status on strength and dose response of the association</i> . Abstract LB-446. Presented at: American Association for Cancer Research (AACR) 102nd annual meeting. 2–6 April 2011, Orlando, FL. Accessed at: <a href="http://www.abstractsonline.com">www.abstractsonline.com</a> on 19 April 2011
	1284				DeVita, VT. 2008. <i>Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma</i> . In: VT DeVita, TS Lawrence, and SA Rosenberg (Eds.). DeVita, Hellman, and Rosenberg's cancer: Principles & practice of oncology. Wolters Kluwer/ Lippincott Williams & Wilkins
	1285				Endo-Capron S, A Reiner, X Janson, L Kheuang, and MC Jaurand. 1993. <i>In vitro response of rat mesothelial cells to talc samples in genotoxicity assays (sister chromatid exchanges and DNA repair)</i> . Toxicol. In Vitro 7:7–14
	1286				DHHS. 1985. Asbestos in talc. Memorandum to W. Gary Flamm (Director, Office of Toxicology Sciences) from QRAC (Quantitative Risk Assessment Committee), Department of Health & Human Services, dated June 6, 1985
	1287	9/25/13	X	Rec'd	FDA Mission Statement: About FDA. What We Do. Available at: <a href="http://www.fda.gov/AboutFDA/WhatWeDo/default.htm">www.fda.gov/AboutFDA/WhatWeDo/default.htm</a> . Accessed August 28, 2013
	1288				FDA. 2006. Database of Select Committee on GRAS Substances (SCOGS) reviews. Talc (basic magnesium silicate). Last updated October 31, 2006. Available at: <a href="http://www.accessdata.fda.gov/scripts/fcn/fcnDetailNavigation.cfm?rpt=scogsListing&amp;id=345">http://www.accessdata.fda.gov/scripts/fcn/fcnDetailNavigation.cfm?rpt=scogsListing&amp;id=345</a> . Accessed November 15, 2010
	1289				FDA. 2011. CFR Title 21 Volume 3, revised April 1, 2011. 21CFR182.2437. Available at: <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.2437">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.2437</a> . Searched on June 1, 2012

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1290	9/25/13	X	Demonstrative	Gates, MA, SS Tworoger, KL Terry, L Titus-Ernstoff, B Rosner, I De Vivo, DW Cramer, and SE Hankinson. 2008. <i>Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer</i> . Cancer Epidemiol. Biomarkers Prev. 17:2436-2444
	1291	10/1/13	X	Demonstrative	Gates, MA, BA Rosner, JL Hecht, and SS Tworoger. 2010. <i>Risk factors for epithelial ovarian cancer by histologic subtype</i> . Am. J. Epidemiol. 171(1):45-53. Epub 2009 Nov 12
	1292				Gertig DW, DJ Hunter, DW Cramer, GA Colditz, Speizer FE, Willett WC, Hankinson SE. 2000 <i>Prospective study of talc use and ovarian cancer</i> . J. Natl. Cancer Inst. 92(3):249-252
	1293				Hamilton, TC, H Fox, CH Buckley, WJ Henderson, and K Griffiths. 1984. <i>Effects of talc on the rat ovary</i> . Brit. J. Experimental Pathol. 65:101-106
	1294				Hankinson, SE, and KN Danforth. 2006. <i>Ovarian cancer</i> . In: D Schottenfeld and JF Fraumeni, Jr. (Eds.). Cancer epidemiology and prevention Oxford University Press, pp. 1013-1026
	1295	9/25/13	X	Demonstrative	Harlow B L, DW Cramer, JA Baron, L Titus-Ernstoff, and E. Greenberg. 1998. <a href="#"><u>Psychotropic medication use and risk of epithelial ovarian cancer</u></a> . Cancer Eidemiol. Biomarkers & Prev. 7:697-702. August 1998.
	1296				Hillegass, JM, A Shukla, MB MacPherson, JP Bond, C Steele, and BT Mossman. 2010. <i>Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1)</i> . J. Toxicol. Environ. Health Part A, 73:423-436
	1297				Holschneider, C.H., and J.S. Berek. 2000. <i>Ovarian cancer: Epidemiology, biology, and prognostic factors</i> . Semin. Surg. Oncol. 19(1):3-10
	1298				Howlader, N, AM Noone, M Krapcho, N Neyman, R Aminou, W Waldron, SF Altekruse, CL Kosary, J Ruhl, Z Tatalovich, H Cho, A Mariotto, MP Eisner, DR Lewis, HS Chen, ED Feuer, KA Cronin, and BK Edwards. <i>SEER cancer statistics review, 1975-2008</i> . National Cancer Institute 2011 [cited. Available from <a href="http://seer.cancer.gov/csr/1975_2008/">http://seer.cancer.gov/csr/1975_2008/</a> , based on November 2010 SEER data submission, posted to the SEER web site, 2011]
	1299				Huncharek M, JF Geschwind, and B Kupelnick. 2003. <i>Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: A meta-analysis of 11,933 subjects from sixteen observational studies</i> . Anticancer Res. 23 1955-1960
	1300				IARC. 1987. IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 42. Silica and some silicates. World Health Organization, International Agency for Research on Cancer
	1301				IARC. 2006. Preamble: IARC Monographs on the evaluation of carcinogenic risks to humans. World Health Organization, International Agency for Research on Cancer. Available at: <a href="http://monographs.iarc.fr/ENG/Preamble/index.php">http://monographs.iarc.fr/ENG/Preamble/index.php</a>
	1302				IARC. 2010. IARC Monographs on the evaluation of carcinogenic risks to humans: Volume 93, Carbon black, titanium dioxide, and talc. Available at: <a href="http://monographs.iarc.fr/ENG/Monographs/PDFs/93-talc.pdf">http://monographs.iarc.fr/ENG/Monographs/PDFs/93-talc.pdf</a> . International Agency for Research on Cancer
	1303				IARC. 2012a. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100C. A review of human carcinogens: Arsenic, metals, fibres, and dusts. Available at: <a href="http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php">http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php</a> . World Health Organization, International Agency for Research on Cancer
	1304				IARC. 2012b. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E. A review of human carcinogens: Personal habits and indoor combustions. Available at: <a href="http://monographs.iarc.fr/ENG/Monographs/vol100E/index.php">http://monographs.iarc.fr/ENG/Monographs/vol100E/index.php</a> . World Health Organization, International Agency for Research on Cancer
	1305				IARC. 2012c. Agents classified by the IARC Monographs, volumes 1-104. Available at: <a href="http://monographs.iarc.fr/ENG/Classification/index.php">http://monographs.iarc.fr/ENG/Classification/index.php</a> . Last updated March 27, 2012. Accessed June 11, 2012
	1306				Keskin N, Teksen YA, Ongun EG, Ozay Y, Saygh H. 2009 <i>Does long-term talc exposure have a carcinogenic effect on the female genital system of rats? An experimental pilot study</i> . Arch. Gynecol. Obstetrics 280:925-931
	1307				NCI. 1994. Abortion and possible risk for breast cancer: analysis and inconsistencies. October 26, 1994 (press release). National Cancer Institute
	1308				NCI. 2011a. FDA approval for talc. Cancer drug information. Last updated January 1, 2011. National Cancer Institute. Available at: <a href="http://www.cancer.gov/cancertopics/druginfo/fda-talc">http://www.cancer.gov/cancertopics/druginfo/fda-talc</a> . Accessed June 1, 2012
	1309				NCI. 2011a. What you need to know about ovarian cancer. Accessed September 28, 2011. Available from <a href="http://www.cancer.gov/cancertopics/wyntk/ovary/page4">http://www.cancer.gov/cancertopics/wyntk/ovary/page4</a> . National Cancer Institute
	1310				NCI. 2012. Ovarian cancer. Available at: <a href="http://www.cancer.gov/cancertopics/types/ovarian">http://www.cancer.gov/cancertopics/types/ovarian</a> . Accessed 6/11/2012. National Cancer Institute
	1311				NRC. 1983. Risk assessment in the federal government: Managing the process. National Research Council on the Institutional Means for Assessment of Risks to Public Health, Commission on Life Sciences. National Academy Press, Washington, DC



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1312				NTP. 1993. National Toxicology Program (NTP) technical report (NTP TR 421) on the toxicology and carcinogenesis studies of talc in F344/N rats and B6C3F1 mice. U.S. Department of Health and Human Services, NTP TR 421, National Institutes of Health NIH Publication 93-3152
	1313	9/25/13	X	Rec'd	NTP. 2000a. Call for comment: RoC 10th proposed. National Toxicology Program. Federal Register: Volume 65, Number 66 [Notices], 17889–17891. Accessed at <a href="http://ntp.niehs.nih.gov/go/11282">http://ntp.niehs.nih.gov/go/11282</a> . Accessed November 15, 2010
	1314				NTP. 2000b. Public comments: 10th report on carcinogens. Public comments on talc. National Toxicology Program. Available at: <a href="http://ntp.niehs.nih.gov/index.cfm?objectid=E9CC41BE-F1F6-975E-747EC913205B706F#talc">http://ntp.niehs.nih.gov/index.cfm?objectid=E9CC41BE-F1F6-975E-747EC913205B706F#talc</a> Accessed November 15, 2010
	1315				NTP. 2004. Vision. <i>Toxicology in the 21<sup>st</sup> Century: The Role of the National Toxicology Program</i>
	1316	9/25/12	X	Rec'd	NTP. 2004. Call for public comments on 21 substances, mixtures and exposure circumstances proposed for listing in the report on carcinogens. Twelfth Edition. National Toxicology Program. Available at: <a href="http://www.federalregister.gov/articles/2004/05/19/04-11359/nationaltoxicology-program-call-for-public-comments-on-21-substances-mixtures-and-exposure">http://www.federalregister.gov/articles/2004/05/19/04-11359/nationaltoxicology-program-call-for-public-comments-on-21-substances-mixtures-and-exposure</a> . Accessed November 10, 2010. Last updated May 19, 2004
	1317	9/25/13	X	Rec'd	NTP 2005a. Report on carcinogens; status of nominations to the 12th report on carcinogens (RoC): Request for comments and nominations of scientific experts. Department of Health and Human Services, National Institutes of Health. National Toxicology Program. Federal Register: October 18, 2005 (70(200): 60548–60554. Available at <a href="http://ntp.niehs.nih.gov/files/12thRoCFR.pdf">http://ntp.niehs.nih.gov/files/12thRoCFR.pdf</a> . Accessed November 15, 2010
	1318				NTP. 2005b. Carcinogens listed in the eleventh report, Part B. Reasonably anticipated to be a human carcinogen. Available at <a href="http://ntp.niehs.nih.gov/ntp/roc/eleventh/reason.pdf">http://ntp.niehs.nih.gov/ntp/roc/eleventh/reason.pdf</a> . Accessed November 15, 2010
	1319				NTP. 2005c. Carcinogens listed in the eleventh report, Part B. Known to be a human carcinogen. Available at <a href="http://ntp.niehs.nih.gov/ntp/roc/eleventh/known.pdf">http://ntp.niehs.nih.gov/ntp/roc/eleventh/known.pdf</a> . Accessed November 15, 2010
	1320				NTP. 2011. Report on carcinogens, twelfth edition. U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program. Available at: <a href="http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf">http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf</a>
	1321				Ozols, R.F., S.C. Rubin, G.M. Thomas, and S.J. Robboy. 2005. <i>Epithelial ovarian cancer</i> . In: Principles and practices of gynecologic oncology - 4th edition. In: W.J Hoskins, R.C Young, M Markman, CA Perez, R Barakat and M Randall (Eds.). Lippincott Williams & Wilkins, New York, Pp. 895–988
	1322				Schorge, JO, SC Modesitt, RL Coleman, DE Cohn, ND Kauff, LR Duska, and TJ Herzog. 2010. <i>SGO white paper on ovarian cancer: Etiology, screening and surveillance</i> . Gynecol. Oncol. 119(1):7–17
	1323				Shukla, A, MB MacPherson, J Hillegass, ME Ramos-Nino, V Alexeeva, PM Vacek, JP Bonds, HI Pass, C Steele, and BT Mossman. 2009. <i>Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity</i> . Am. J. Respir., Cell Molecular Biol. 41:114–123
	1324				Troisi, R, and P Hartage. 2000. Ovarian cancer. In: MB Goldman and MC Hatch (Eds.). <i>Women and health</i> . Academic Press, San Diego, CA, pp. 907–915
	1325				Tsilidis, KK, NE Allen, TJ Key, L Dossus, A Lukanova, K Bakken, E Lund, A Fournier, K Overvad, L Hansen, A Tjonneland, V Fedirko, S Rinaldi, I Romieu, F Clavel-Chapelon, P Engel, R Kaaks, M Schutze, A Steffen, C Bamia, A Trichopoulou, D Zylis, G Masala, V Pala, R Galasso, R Tumino, C Sacerdote, HB Bueno-de-Mesquita, FJ van Duijnhoven, MG Braem, NC Onland-Moret, IT Gram, L Rodriguez, N Travier, MJ Sanchez, JM Huerta, E Ardanaz, N Larranaga, K Jirstrom, J Manjer, A Idahl, N Ohlson, KT Khaw, N Wareham, T Mouw, T Norat, and E Riboli. 2011. <i>Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition</i> . Br. J. Cancer 105(9):1436–1442
	1326				U.S. EPA. 2012. Integrated Risk Information Service (IRIS) glossary. U.S. Environmental Protection Agency. Available at: <a href="http://www.epa.gov/IRIS/">http://www.epa.gov/IRIS/</a> . Last accessed June 11, 2012
	1327				Wehner, AP, AS Hall, RE Weller, EA Lepel, and RE Schirmer. 1985. <i>Do particles translocate from the vagina to the oviducts and beyond?</i> Food Chem. Toxicol. 23:367-372.
	1328				Wehner, AP, RE Weller, and EA Lepel. 1986. <i>On talc translocation from the vagina to the oviducts and beyond</i> . Food Chem. Toxicol. 24:329-338
	1329	10/2/13	X	Demonstrative	Whittemore, AS, ML Wu, RS Paffenbarger, Jr., DL Sarles, JB Kampert, S Grosser, DL Jung, S Ballon, and M Hendrickson. 1988. <i>Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee</i> . Am. J. Epidemiol. 128(6):1228–1240
	1330				Barnhart, KT, A Izquierdo, ES Pretorius, DM Shera, M Shabbout, and A Shaunik (2006) <i>Baseline Dimensions of the Human Vagina</i> . Human Reproduction 21: 1618-1822

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1331				Carlson, BM. (2009) <i>Human Embryology and Developmental Biology</i> , 4th Ed, Mosby Elsevier, Philadelphia
	1332				Chakraborty, J and L Nelson (1975) <i>Fate of Surplus Sperm in the Fallopian Tube of the White Mouse</i> . <i>Biology of Reproduction</i> 12: 455-463
	1333				Cotran, RS, V Kumar, and T Collins (1999) <i>Robbins Pathologic Basis of Disease</i> , 6th Edition, W.B Saunders Company, Philadelphia
	1334				Crafts, RC (1979) <i>A Textbook of Human Anatomy</i> , 2nd Edition, John Wiley & Sons, New York. *
	1335				Cramer, DW, WR Welch, RS Berkowitz, and JJ Godleski (2007) <i>Presence of Talc in Lymph Nodes of a Woman with ovarian Cancer and Long-term Exposure to Genital Talc</i> . <i>Obstetrics and Gynecology</i> , 110:498-501
	1336				DeBoer, CH (1972) <i>Transport of Particulate Matter through the Human Female Genital Tract</i> . <i>Journal of Reproduction and Fertility</i> , 28:295-297
	1337				DeSesso, JM (1995) <i>Anatomical Relationships of Urinary Bladders Compared: Their Potential Role in the Development of Bladder Tumors in Humans and Rats</i> . <i>Food and Chemical Toxicology</i> , 33, pp. 705-714
	1338				diZerega, GS and KE Rodgers (1992) <i>The Peritoneum</i> , Springer-Verlag, New York. *
	1339				Drake, RL, AW Vogl and AWM Mitchell (2010) <i>Gray's Anatomy for Students</i> , 2nd Edition, Churchill Livingstone, Philadelphia
	1340				Dym, M (1988) <i>The Male Reproductive System</i> . Chapter 30 in <i>Cell and Tissue Biology</i> , 6 <sup>th</sup> Edition, LM Weiss, ed., Urban & Schwartzberg, Baltimore, pp. 931-972
	1341				Eddy, EM and DA O'Brien (1994) <i>The Spermatozoon</i> . Chapter 2 in <i>The Physiology of Reproduction</i> , 2nd Edition, E Knobil and JD Neill, Eds., Raven Press, New York, pp 29-78
	1342				Ferrer, J, JF Montes, MA Villarino, RW Light, and J Garcia-Valero (2002) <i>Influence of Particle Size on Extrapleural Talc Dissemination after Talc Slurry Pleurodesis</i> . <i>Chest</i> , 122: 1018-1027
	1343				Gates, MA, BA Rosner, JL Hecht and SS Tworoger (2010) <i>Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype</i> . <i>American Journal of Epidemiology</i> , 171:45-53
	1344				Goodman, JI (1995) <i>An Analysis of the National Toxicology Program's (NTP) Technical Report (NTP TR 421) on the Toxicology and Carcinogenesis Studies of Talc</i> . <i>Regulatory Toxicology and Pharmacology</i> , 21:244-249
	1345				Hamilton, TC, H Fox, CH Buckley, WJ Henderson, and K Griffiths (1984) <i>Effects of Talc on the Rat Ovary</i> . <i>British Journal of Experimental Pathology</i> , 65:101-106
	1346				Hannibal, CG, MA Rossing, KG Wicklund, KL Cushing-Haugen (2008) <i>Analgesic Use and Risk of Epithelial Ovarian Cancer</i> . <i>American Journal of Epidemiology</i> , 167:1430-1437
	1347				Hebel, R and Stromberg, MW (1986) <i>Anatomy and Embryology of the Laboratory Rat</i> , BioMed Verlag, Wörthsee, Germany
	1348				Heller DS, Westhoff C, Gordon RE, Katz N. (1996) <i>The Relationship Between Perineal Cosmetic Talc Usage and Ovarian Talc Particle Burden</i> . <i>American Journal of Obstetrics and Gynecology</i> , 174:1507-1510
	1349				Henderson, WJ, CAF Joslin, AC Turnbull and K Griffiths (1971) <i>Talc and Carcinoma of the Ovary and Cervix</i> . <i>The Journal of Obstetrics and Gynaecology of the British Commonwealth</i> , 87:266-272
	1350	9/30/13	X	Demonstrative	Henderson, WJ, TC Hamilton, MS Bayliss, CG Pierrepont and K Griffiths. (1986) <i>The Demonstration of Migration of Talc from the Vagina and Posterior Uterus to the Ovary in the Rat</i> . <i>Environmental Research</i> , 40: 47-250
	1351				Jones, RE. (1997) <i>Human Reproductive Biology</i> , 2nd Edition, Academic Press, San Diego *
	1352				Junqueiro, JC and J Carneiro. (2005) <i>Basic Histology</i> , 11th Edition, McGraw-Hill Medical Publishing, New York
	1353				Kessel, RG and RH Kardon. (1979) <i>Tissues and Organs: A Text-atlas of Scanning Electron Microscopy</i> . W H Freeman and Company, San Francisco
	1354				Kölle, S, S Dubielzig, S Reese, A Wehrend, P König and W Kummer. (2009) <i>Ciliary Transport, Gamete Interaction, and Effects of the Early Embryo in the Oviduct: Ex Vivo Analyses Using a New Digital Videomicroscopic System in the Cow</i> . <i>Biology of Reproduction</i> , 81:267-274
	1355				Kunz, G, D Beil, H Deiniger, A Einspanier, G Mall and G Leyendecker. (1997) <i>The Uterine Peristaltic Pump: Normal and Impeded Sperm Transport within the Female Genital Tract</i> . <i>Advances in Experimental Medicine and Biology</i> , 424:267-277
	1356				Leyendecker G, G Kunz, L Wildt, D Beil and H Deiniger. (1996) <i>Uterine Hyperperistalsis and Dysperistalsis as Dysfunctions of the Mechanism of Rapid Sperm Transport in Patients with Endometriosis and Infertility</i> . <i>Human Reproduction</i> , 11:1542-1551
	1357				Lin, HW, YY Tu, SY Lin, WJ Su, WL Lin, WZ Lin, SC Wu and YL Lai. (2011) <i>Risk of Ovarian Cancer in Women with Pelvic Inflammatory Disease: A Population-based Study</i> . <i>The Lancet Oncology</i> , 12:900-904

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1358				Mescher, AL. (2010) <i>Junqueira's Basic Histology Text &amp; Atlas</i> , 12th Edition, McGraw Hill, New York
	1359	9/27/13	X	Demonstrative	Merritt, MA, AC Green, CM Nagle, PM Webb, Australian Cancer (Ovarian Cancer) Group, and Australian Ovarian Cancer Group. (2008) <i>Talcum Powder, Chronic Pelvic Inflammation and NSAIDs in Relation to Risk of Epithelial Ovarian Cancer</i> . International Journal of Cancer, 122:170-176
	1360				Middleton EA, Daniel JC, Know KS, Williams K. (2011) <i>PET positive pleural plaques decades after pleurodesis: Mesothelioma?</i> Southwest Journal of Pulmonary Critical Care 2:6-10
	1361				Moore, KL and AF Dalley. (2006) <i>Clinically Oriented Anatomy</i> , 5th Edition, Lippincott Williams & Wilkins, Philadelphia York
	1362				Ness, RB, JA Grisso, C Cottreau, J Klapper, R Vergona, JE Wheeler, M Morgan and JJ Schlesselman. (2000) <i>Factors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer</i> . Epidemiology, 11:111-117
	1363				NTP (National Toxicology Program) (1993) <i>National Toxicology Program (NTP) Technical Report (NTP TR 421) on the Toxicology and Carcinogenesis Studies of Talc in F344/N Rats and B6C3F1 Mice</i> . US Department of Health and Human Services, NTP TR 421, National Institutes of Health NIH Publication 93-3152
	1364				Oberdörster, G. (1995) <i>Lung Particle Overload: Implications for Occupational Exposures to Particles</i> . Regulatory Toxicology and Pharmacology, 27: 123-135
	1365				Olver, FWJ, DW Lozier, RF Boisvert and CW Clark (2010) NIST (National Institute of Standards and Technology) Handbook of Mathematical Functions, 19.33 Surface Area of Triaxial Ellipsoids, <a href="http://dlmf.nist.gov/19.33">http://dlmf.nist.gov/19.33</a> viewed 24 February 2012
	1366				Ozaki, K, JK Haseman, JR Hailey, RP Maronpot and A Nyska. (2002) <i>Association of Adrenal Pheochromocytoma and Lung Pathology in Inhalation Studies with Particulate Compounds in the Male F344 Rat – The National Toxicology Program Experience</i> . Toxicologic Pathology, 30:263-270
	1367				Page, EW, C. A. Villee, and DB Villee. (1976) <i>Human Reproduction: The Core Content of Obstetrics, Gynecology and Perinatal Medicine</i> , 2nd Edition, W. B. Saunders Company, Philadelphia
	1368				Parazzini, F, E Negri, E Ricci, S Franceschi and C La Vecchia. (1996) <i>Correlates of Oral Contraceptive Use in Italian Women, 1991-93</i> . Contraception, 54:101-106
	1369				Phillips, JC, PJ Young, K Hardy and SD Gangolli. (1978) <i>Studies on the Absorption and Disposition of 3H-labelled Talc in the Rat, Mouse, Guinea Pig and Rabbit</i> . Food and Cosmetic Toxicology, 16:161-163
	1370				Pinheiro, SP, SS Tworoger, DW Cramer, BA Rosner and SE Hankinson. (2009) <i>Use of Nonsteroidal Antiinflammatory Agents and Incidence of Ovarian Cancer in 2 Large Prospective Cohorts</i> . American Journal of Epidemiology, 169:1378-1387
	1371				Pinheiro, SP, MA Gates, I DeVivo, BA Rosner, SS Tworoger, L Titus-Ernstoff, SE Harkinson and DW Cramer. (2010) <i>Interaction between Use of Non-steroidal Anti-inflammatory Drugs and Selected Genetic Polymorphisms in Ovarian Cancer Risk</i> . International Journal of Molecular Epidemiology and Genetics, 1:320-331
	1372				Prizment, AE, AR Folsom and KE Anderson. (2010) <i>Nonsteroidal Anti-inflammatory drugs and Risk for Ovarian and Endometrial Cancers in the Iowa Women's Health Study</i> . Cancer Epidemiology, Biomarkers and Prevention, 19:435-442
	1373				Ramsey, EM. (1982) <i>The Placenta, Human and Animal</i> , Praeger, New York
	1374				Risch, HA and GR Howe. (1995) <i>Pelvic Inflammatory Disease and the Risk of Epithelial Ovarian Cancer</i> . Cancer Epidemiology, Biomarkers and Prevention, 4:447-451
	1375				Suarez, SS and AA Pacey. (2006) <i>Sperm Transport in the Female Reproductive Tract</i> . Human Reproduction Update, 12:23-37
	1376				Shu, XO, LA Brinton, YT Gao and JM Yuan. (1989) <i>Population-based Case-Control Study of Ovarian Cancer in Shanghai</i> . Cancer Research, 49:3670-3674
	1377				Venter, PF and M Iturralde. (1979) <i>Migration of a Particulate Radioactive Tracer from the Vagina to the Peritoneal Cavity and Ovaries</i> . South African Medical Journal, 55: 917 -919
	1378				Warwick, R and PL Williams. (1973) <i>Gray's Anatomy</i> , 35th British Edition, W. B. Saunders Company, Philadelphia
	1379				Wehner, AP. (2002) <i>Cosmetic Talc Should Not be Listed as a Carcinogen: Comments on NTP's Deliberations to List Talc as Carcinogen</i> . Regulatory Toxicology and Pharmacology, 36:40-50
	1380				Wernli, KJ, PA Newcomb, JM Hampton, A Trentham-Dietz and KM Egan. (2008) <i>Inverse Association of NSAID Use and Ovarian Cancer in Relation to Oral Contraceptive Use and Parity</i> . British Journal of Cancer, 98:1781-1783
	1381				Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. (2009) <i>Markers of inflammation and risk of ovarian cancer in Los Angeles County</i> . International Journal of Cancer. 124:1409-1415

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1382				Blank MM, et al. 2012. <i>Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study</i> . British Journal of Cancer. 106:596-602
	1383				British Thoracic Society 1979 <i>A survey of the long-term effects of talc and kaolin pleurodesis</i> . Br J Dis Chest 73:285-288
	1384				Coggiola, et al. 2003. <i>An update a mortality study of talc miners and millers in Italy</i> . Amer J Ind Med 44:63-69
	1385				Cook, LS, et al. 1997. <i>Perineal powder exposure and the risk of ovarian cancer</i> . Am. J. Epidemio. 145:459-465
	1386				Cramer D W, et al; 1984. <a href="#"><i>Dietary Animal Fat in Relation to Ovarian Cancer Risk</i></a> . Ob Gyn 63(6):833-838
	1387				Gates MA, et al. 2008. <i>Talc Use, Variants of the GSTM1, GSTT1, and NAT2 Genes, and Risk of Epithelial Ovarian Cancer</i> . Caner Epidemiol Biomark. Prev 17:2436-44
	1388				Gates MA, et al. 2010. <i>Risk factors for epithelial ovarian cancer by histologic subtype</i> . Amer J Epid. 171:45-53
	1389				Genkinger JM, et al. 2006. <i>Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies</i> . Cancer Epidemiology, Biomarkers & Prevention. 15(2):364-72
	1390				Honda Y, et al. 2002. <i>Mortality among workers at a talc mining and milling facility</i> . Ann Occ Hyg 46:575-585
	1391				Hunt I, et al. 2007. <i>Is pleurodesis talc safe for young patients following primary spontaneous pneumothorax?</i> Inter Cardio Vasc Thorac Surg 6:117-120
	1392				IARC 1991. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 51, Coffee, Tea, Methylxanthines and Methylglyoxal
	1393	10/2/13	X	Demonstrative	IARC 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 93, Carbon Black, Titanium Dioxide, and Talc.
	1394				Langseth H, et al. 2004. <i>Ovarian cancer and occupational exposure among pulp and paper employees in Norway</i> . Scand J Work Envir Health 30:356-61
	1395				Rosenblatt KA, et al. 1998. <i>Characteristics of women who use perineal powders</i> . Obstet Gynecol 92:753
	1396				Rubino GF, et al. 1976 <i>Mortality study of talc miners and millers</i> . J Occ Med 18:186-193
	1397	10/1/13	X	Demonstrative	Rubino GF, et al. 1979. <i>Mortality and morbidity among talc miners and millers in Italy</i> . Pathotox 357-363
	1398				Schultz M, et al. 2007. <i>No association of consumption of animal foods with risk of ovarian cancer</i> . Cancer Epidemiology, Biomarkers & Prevention. 16:852-5
	1399				Selevan SG, et al. 1979. <i>Mortality patterns among miners and millers of non-asbestiform talc: preliminary report</i> . Pathotox 379-388
	1400				Stanton MF, et al. 1981. <i>Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals</i> . J Nat Cancer Inst 67:965-975
	1401				Wergeland E, et al. 1990. <i>Morbidity and mortality in talc exposed workers</i> . Amer J Ind Med 17:505-513
	1402				Wild P, et al. 2002. <i>A cohort mortality and nested case-control study of French and Austrian talc workers</i> . Occ Env Med 59:98-105
	1403				Wild P. 2006. <i>Lung cancer risk and talc not containing asbestiform fibres: a review of the epidemiological evidence</i> . Occ Env Med 63:4-9
	1404				American Cancer Society. How many women get ovarian cancer? Available at: <a href="http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-key-statistics">http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-key-statistics</a>
	1405				American Cancer Society. What are the risk factors for ovarian cancer? Available at: <a href="http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-what-causes">http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-what-causes</a>
	1406				IARC. Globocan 2008. Available at: <a href="http://globocan.iarc.fr/">http://globocan.iarc.fr/</a>
	1407				NCI. Surveillance Epidemiology and End Results. Available at: <a href="http://seer.cancer.gov/faststats/selections.php?#Output">http://seer.cancer.gov/faststats/selections.php?#Output</a>
	1408	10/1/13	X	Demonstrative	Booth M, Beral V, Smith P. <i>Risk factors for ovarian cancer: A case-control study</i> . Br J Cancer 1989; 60:592-598
	1409	10/2/13	X	Demonstrative	Chang S, Risch HA. <i>Perineal talc exposure and risk of ovarian carcinoma</i> . Cancer 1997; 79:2396-2401
	1410				Coggiola M, Bosio D, Pira E, Piolatto PG, La Vecchia C, Negri E, Michelazzi M, Bacaloni A. <i>An update of a mortality study of talc miners and millers in Italy</i> . Am J Ind Med 2003; 44:63-69
	1411	10/2/13	X	Demonstrative	Cook LS, Kamb ML, Weiss NS. <i>Perineal powder exposure and the risk of ovarian cancer</i> . Am J Epidemiol 1997; 145(5):459-465



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1412				De Boer CH. <i>Transport of particulate matter through the human female genital tract.</i> J Reprod Fertil 1972; 28:295–297
	1413				Edelstam GAB, Sjösten ACE, Ellis H. <i>Retrograde migration of starch in the genital tract of rabbits.</i> Inflammation 1997; 21(5):489–499
	1414				Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171(1):45–53
	1415				Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson A-M, Narod SA, Ghadirian P. <i>Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study.</i> Am J Obstet Gynecol 1998; 179(2): 403–410
	1416				Green A, Purdie D, Bain C, Siskind V, Russel P, Quinn M, Ward B, and the Survey of Women's Health Study Group. <i>Tubal sterilization, hysterectomy and decreased risk of ovarian cancer.</i> Int J Cancer 1997; 71:948–951.
	1417				Griffiths K, Henderson AJ, Chandler JA, Joslin CAF. <i>Ovarian cancer: some new analytical approaches.</i> Postgrad Med J 1973; 49:69–72
	1418				Hamilton TC, Fox H, Buckley CH, Henderson WJ, Griffiths K. <i>Effects of talc on the rat ovary.</i> Br J Exp Path 1984; 65:101–106
	1419	10/2/13	X	Demonstrative	Harlow BL, Weiss NS. <i>A case-control study of borderline ovarian tumors: The influence of perineal exposure to talc.</i> Am J Epidemiol 1989; 130(2):390–394
	1420				Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL. <i>Folate, vitamin B6, vitamin B12, methionine and alcohol intake in relation to ovarian cancer risk.</i> Int J Cancer 2001; DOI: 10.1002/ijc.26455
	1421				Hartge P, Hoover R, Leshner LP, McGowan L. <i>Talc and ovarian cancer.</i> JAMA 1983; 250(4):1844
	1422				Henderson WJ, Hamilton TC, Baylis MS, Pierrepont CG, Griffiths K. <i>The demonstration of the migration of talc from the vagina and posterior uterus to the ovary in the rat.</i> Environ Res 1986; 40:247–250
	1423				Henderson WJ, Joslin CAF, Turnbull AC, Griffiths K. <i>Talc and carcinoma of the ovary and cervix.</i> J Obstet Gynaecol Br Commonw 1971; 78:266–272
	1424				International Agency for Research on Cancer. <i>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.</i> Volume 93. Carbon Black, Titanium Dioxide, and Talc. Lyon France; 2010
	1425				Jordan SJ, Green AC, Whiteman DC, Webb M, for the Australian Ovarian Cancer Study Group and the Australian Cancer Study (Ovarian Cancer). <i>Risk factors for benign serous and mucinous epithelial ovarian tumors.</i> Obstet Gynecol 2007;109:647–654
	1426				Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. <i>Differences in tumor type in low-stage versus high-stage ovarian carcinomas.</i> Int J Gynecol Pathol. 2010 May; 29(3):203–211
	1427				Kölle S, Reese S, Kummer W. <i>New aspects of gamete transport, fertilization, and embryonic development in the oviduct gained by means of live cell imaging.</i> Theriogenology. 2010 Apr 1; 73(6):786–795
	1428				Langseth H, Andersen A. <i>Cancer incidence among male pulp and paper workers in Norway.</i> Scand J Work Environ Health. 2000 Apr; 26(2):99-105
	1429				Langseth H, Andersen A. <i>Cancer incidence among male pulp and paper workers in Norway.</i> Scand J Work Environ Health. 2000 Apr; 26(2):99-105
	1430				Lyons RA, Saridogan E, Djahanbakhch O. <i>The reproductive significance of human Fallopian tube cilia.</i> Hum Reprod Update. 2006; 12(4):363–372
	1431				McLean D, Colin D, Boffetta P, Pearce N. <i>Mortality and cancer incidence in New Zealand pulp and paper mill workers.</i> NZ Med J 2002; 115:186–190
	1432				Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group. <i>Talcum powder, chronic pelvis inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.</i> Int J Cancer 2008; 122:170–176
	1433				Mills PK, Riordan DG, Cress RD, Young HA. <i>Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California.</i> Int J Cancer 2004;112:458–464
	1434				Muscat JE, Huncharek MS. <i>Perineal talc use and ovarian cancer: A critical review.</i> Eur J Cancer Prev 2008; 17:139–146
	1435				Phillips JC, Young PJ, Hardy K, Gangolli SD. <i>Studies on the absorption and disposition of <sup>3</sup>H-labelled talc in the rat, mouse, guinea-pig and rabbit.</i> Fd Cosmet Toxicol 1978; 16:161–163

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1436				Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B, for the Survey f Women's Health Study Group. <i>Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study.</i> Int J Cancer 1995; 62:678-684
	1437				Ramanakumar AV. Parent M-É, Latreille B, Siemiatycki J. <i>Risk of lung cancer following exposure to carbon black, titanium dioxide and talc: Results from two case-control studies in Montreal.</i> Int J Cancer 2008; 122:183-189
	1438				Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit. <i>A survey of the long-term effects of talc and kaolin pleurodesis.</i> Br J Dis Chest 1979; 73:285-288
	1439				Rosenblatt KA, Matthews WA, Darling JR, Voight LF, Malone K. <i>Characteristics of women who use perineal powers.</i> Obstet Gynecol 1998; 92:753-756
	1440				Rosenblatt KA, Szklo M, Rosenshein NC. <i>Mineral fiber exposure and the development of ovarian cancer.</i> Gynecol Oncol 1992; 45:20-25
	1441				Rubino GF, Scansetti G, Piolatto G, Gay G. Mortality and morbidity among talc miners and millers in Italy. In Lemen R, Dement JM, editors. <i>Dusts and Disease, Proceedings of the Conference on Occupational Exposures to Fibrous and Particulate Dust and their Extension into the Environment.</i> Park Forest South, Illinois: Pathofox Publisher, Inc.; 1979:357-363
	1442				Selevan SG, Dement JM, Wagoner JK, Froines JR (1979): <i>Mortality patterns among miners and millers of non-asbestiform talc: Preliminary report.</i> J Environ Pathol Toxicol 2:273-284
	1443				Sjösten ACE, Ellis H, Edelstam GAB. <i>Retrograde migration of glove powder in the human female genital tract.</i> Hum Reprod 2004; 19(4):991-995
	1444				Thomas TL, Steward PA. <i>Mortality from lung cancer and respiratory disease among pottery workers exposed to silica and talc.</i> Am J Epidemiol 1987; 125(1):35-43
	1445				U.S. Department of Health, Education, and Welfare. Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Publication No. 1103. Washington, D.C.: U.S. Government Printing Office; 1964
	1446				Venter PF, Iturralde M. <i>Migration of a particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries.</i> S Afr Med J 1979; 55:917-919
	1447				Wergeland E, Andersen A, Børheim A. <i>Morbidity and mortality in talc-exposed workers.</i> Am J Ind Med 1990; 17:505-513
	1448				Wild P, Leodolter K, Réfrégier M, Schmidt H, Zidek T, Haidinger G. <i>A cohort mortality and nested case-control study of French and Austrian talc workers.</i> Occup Environ Med 2002; 59(2):98-105
	1449				Wild P. <i>Lung cancer risk and talc not containing asbestiform fibres: A review of the epidemiological evidence.</i> Occup Environ Med 2006; 63:4-9
	1450				Wong C, Hempling RE, Piver S, Natarajan N, Mettlin CJ. <i>Perineal talc exposure and subsequent epithelial ovarian cancer: A case-control study.</i> Obstet Gynecol 1999; 93:372-376
	1451				Ayres, TJ, Gross, MM, Wood, CT, Horst, DP, Beyer, RR, & Robinson, JN. (1994). <i>What is a warning and when will it work?</i> In K. R. Laughery Sr., M. S. Wogalter & S. L. Young (Eds.), <i>Human factors perspective on warnings: Selections from Human Factors and Ergonomics Society annual meetings.</i> Santa Monica, CA: Human Factors and Ergonomics Society
	1452				Ayres, TJ, Wood, CT, Schmidt, RA, Young, DE, & Murray, J. (1998). <i>Effectiveness of warning labels and signs: An update on compliance research.</i> Paper presented at the Proceedings of the Silicon Valley Ergonomics Conference & Exposition (ErgoCon '98)
	1453				CRE. (2000). Comments by CRE on the Listing Proposed for Talc not Containing Asbestiform Fibers in the Report on Carcinogens, Tenth Edition
	1454				deTurck, M. A. (1995). <i>Developing and defending product warnings: A communication theory perspective.</i> Product Safety & Liability Reporter, 23(10), 274-281 *
	1455				Dorris, AL. (1991). <i>Product warnings in theory and practice: Some questions answered and some answers questioned.</i> Paper presented at the Proceedings of the Human Factors and Ergonomics Society: 35th Annual Meeting
	1456				Friedmann, K. (1988). <i>The effect of adding symbols to written warning labels on user behavior and recall.</i> Human Factors, 30(4), 507-515
	1457				Huntley-Fenner, G., Sala, J. B., & Wood, C. T. (2007). <i>A study of the impact of California's proposition 65 warnings on consumers' safety related awareness and behaviors.</i> Paper presented at the Society for Risk Analysis Proceedings Abstracts, San Antonio, TX
	1458				IARC. (2006). <i>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Preamble.</i> Lyon, France

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1459				McCarthy, RL, Finnegan, JP, Krumm-Scott, S, & McCarthy, GE. (1984). <i>Product information presentation, user behavior, and safety</i> . Paper presented at the Proceedings of the Human Factors and Ergonomics Society: 28th Annual Meeting
	1460				McCarthy, RL, Robinson, JN, Finnegan, JP, & Taylor, RK. (1982). <i>Warnings on consumer products: Objective criteria for their use</i> . Paper presented at the Proceedings of the Human Factors and Ergonomics Society: 26th Annual Meeting
	1461				Miller, GA. (1956). <i>The magical number seven plus or minus two: some limits on our capacity for processing information</i> . Psychological Review, 63(2), 81-97
	1462				Miller, JM, & Lehto, MR. (2001). <i>Warnings &amp; safety instructions: annotated and indexed</i> (4th ed.). Ann Arbor, Mich.: Fuller Technical Publications
	1463				Photographs of Baby Powder
	1464				Photographs of Shower to Shower
	1465				Photographs of pure cosmetic grade talc
	1466				Plaintiff's Medical Specials
	1467				Plaintiff's medical and billing records produced with Plaintiff's Response to J&J's First Request for Production (BergRspToRFP00001-01172)
	1468				Federal Reference Manual on Scientific Evidence (3d ed. 2011)
	1469				IARC Preamble.
	1470				IARC, <i>Agents Classified by the IARC Monographs, Volumes 1-105</i> (Specifically including VOLUME 93 Carbon Black, Titanium Dioxide, and Talc
	1471	10/2/13	X	Demonstrative	Cosmetic Ingredient Review Committee (CIR), Safety Assessment of Talc as Used in Cosmetics, April 12, 2013.
	1472				Cosmetic Ingredient Review Committee (CIR), Safety Assessment of Talc as Used in Cosmetics, Preliminary Draft Circulated for Public Comment. Available at Source: <a href="http://www.cir/safety.org/sites/default/files/talc122012tent_faa_final%20for%20posting.pdf">http://www.cir/safety.org/sites/default/files/talc122012tent_faa_final%20for%20posting.pdf</a>
	1473	9/25/13	X	Rec'd	<i>Talc: Consumer Uses and Health Perspectives</i> , Regulatory, Toxicology, and Pharmacology 21, 211-215 (1995)
	1474	9/25/13	X	Rec'd	DEPARTMENT OF HEALTH AND HUMAN SERVICES, Food and Drug Administration, 21 CFR Part 347, [Docket No. 78N-0021]:Talc; Consumer Uses and Health Perspectives; Public Meetings, AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public meetings, available at <a href="http://www.gpo.gov/fdsys/pkg/FR-1994-01-14/html/94-1083.htm">http://www.gpo.gov/fdsys/pkg/FR-1994-01-14/html/94-1083.htm</a>
	1475	9/25/13	X	Rec'd	Transcripts from above proceedings <i>Talc: Consumer Uses and Health Perspectives</i> , January 31, 1994, and Tuesday, February 1, 1994.
	1476				National Toxicology Program's public information about its purpose and function, including information available at <a href="http://ntp.niehs.nih.gov/?objectid=7201637B-BDB7-CEBA-F57E39896A08F1BB">http://ntp.niehs.nih.gov/?objectid=7201637B-BDB7-CEBA-F57E39896A08F1BB</a> (About the NTP); <a href="http://ntp.niehs.nih.gov/?objectid=72016262-BDB7-CEBA-FA60E922B18C2540">http://ntp.niehs.nih.gov/?objectid=72016262-BDB7-CEBA-FA60E922B18C2540</a> (About the Report on Carcinogens); and <a href="http://www.niehs.nih.gov/health/materials/report_on_carcinogens_12th_edition_the_508.pdf">http://www.niehs.nih.gov/health/materials/report_on_carcinogens_12th_edition_the_508.pdf</a> (The Report on Carcinogens)
	1477	9/27/13	X	Rec'd	12th Report on Carcinogens (National Toxicology Program 2011)
	1478				65 Fed. Reg. 17,889-90
	1479				66 Fed. Reg. 13,334, 13,336
	1480				69 Fed. Reg. 28,941-43
	1481				70 Fed. Reg. 60,548, 60,553
	1482				11th Report on Carcinogens (National Toxicology Program 2005)
	1483	9/25/13	X	Rec'd	QRAC (Quantitative Risk Assessment Committee, Department of Health and Human Services, <i>Memorandum: Asbestos in Talc</i> (June 6, 1985)
	1484	9/25/13	X	Rec'd	California Proposition 65 list, at <a href="http://www.oehha.org/prop65/prop65_list/files/P65single072613.pdf">http://www.oehha.org/prop65/prop65_list/files/P65single072613.pdf</a>
	1485				California Proposition 65, Chemicals under consideration, at <a href="http://oehha.ca.gov/prop65/CRNR_notices/admin_listing/abtracking.html">http://oehha.ca.gov/prop65/CRNR_notices/admin_listing/abtracking.html</a>
	1486				Safe Drinking Water and Toxic Enforcement Act of 1986, at <a href="http://www.oehha.org/prop65/law/P65law72003.html">http://www.oehha.org/prop65/law/P65law72003.html</a> ; <a href="http://www.oehha.org/prop65/law/pdf_zip/P65LAW72003.pdf">http://www.oehha.org/prop65/law/pdf_zip/P65LAW72003.pdf</a>
	1487	9/25/13	X	Rec'd	California Proposition 65, <a href="http://oehha.ca.gov/prop65/background/p65plain.html">http://oehha.ca.gov/prop65/background/p65plain.html</a> (Plain language)

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1488				Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype, Am. Journal of Epidemiology 2010; 171:45-53
	1489				John Whysner, <i>Perineal Application of Talc and Cornstarch Powders: Evaluation of Ovarian Cancer Risk</i> . 183(3) Am. J. Obstet. Gynecol. 720-724 (2000)
	1490				Alan Gross, <i>A Meta-Analytical Approach Examining the Potential Relationship Between Talc Exposure and Ovarian Cancer</i> , 5(2) J. Exposure Analysis Envt'l Epidem. 181-195 (1995)
	1491	9/25/13	X	Rec'd	FDA Statement entitled "Talc in Cosmetics," available at <a href="http://www.fda.gov/Cosmetics/ProductandIngredientSafety/SelectedCosmeticIngredients/ucm293184">http://www.fda.gov/Cosmetics/ProductandIngredientSafety/SelectedCosmeticIngredients/ucm293184</a>
	1492	9/25/13	X	Rec'd	Center for Disease Control Public Information pertaining to ovarian cancer, including those sources specifically identified below.
	1493				Basic Information About Ovarian Cancer <a href="http://www.cdc.gov/cancer/ovarian/basic_info/">http://www.cdc.gov/cancer/ovarian/basic_info/</a> ;
	1494				Ovarian Cancer Risk Factors from Centers for Disease Control and Prevention <a href="http://www.cdc.gov/cancer/ovarian/basic_info/risk_factors.htm">http://www.cdc.gov/cancer/ovarian/basic_info/risk_factors.htm</a>
	1495				Ovarian Cancer Prevention from Centers for Disease Control and Prevention <a href="http://www.cdc.gov/cancer/ovarian/basic_info/prevention.htm">http://www.cdc.gov/cancer/ovarian/basic_info/prevention.htm</a> ;
	1496	9/25/13	X	Rec'd	Ovarian Cancer Inside Knowledge Get the Facts about Gynecologic Cancer from Centers for Disease Control and Prevention <a href="http://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf">http://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf</a>
	1497				A-Z list on Center from Centers for Disease Control and Prevention webpage: <a href="http://www.cdc.gov/az/t.html">http://www.cdc.gov/az/t.html</a>
	1498	9/25/13	X	Rec'd	Ovarian Cancer Prevention (PDQ) webpage from National Cancer Institute at the National Institutes of Health <a href="http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient">http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient</a>
	1499	9/25/12	X	Rec'd	Ovarian Cancer Prevention (PDQ) Health Professional Version webpage from National Cancer Institute at the National Institutes of Health <a href="http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional">http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional</a>
	1500				EPA, Integrated Risk Information System, A-Z List of Substances, <a href="http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList&amp;list_type=alpha&amp;view=T">http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList&amp;list_type=alpha&amp;view=T</a> .
	1501				Cathen JA, Epstein SS, and Deutsch ME, <i>Citizen Petition Seeking Carcinogenic Labeling on All Cosmetic Talc Products</i> (1994).
	1502				FDA's Response to the Citizen's Petition cited above
	1503				FDA, <i>Response from the FDA to Mr. Douillet Regarding His Petition Requesting That Cosmetic Talc Be Labeled with an Asbestos Warning</i> , Re: Docket No. 83P-0404 (1986)
	1504				Citizen's Petition for the Response cited
	1505				Epstein SS, <i>Petition Seeking a Cancer Warning on Cosmetic Talc Products</i> (2008).
	1506				Talc: Consumer Uses and Health Perspectives (1994)
	1507				Terry KL, Karageorgi S, Shvetsov, YB, Merritt, MA, et al; <i>Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls</i> . Cancer Prev Res (Phila). 2013 August; 6(8):811-21.
	1508				Kassirer JP and JS Cecil; <i>Inconsistency in Evidentiary Standards for Medical Testimony: Disorder in the Courts</i> . JAMA. September 18, 2002 – Vol. 288, No. 11
	1509				Checkoway H, Pearce N, Kriebel D. <i>Research Methods in Occupational Epidemiology</i> . (2 <sup>nd</sup> ed. 2004) 34:3-16, 59-61, 248
	1510	9/25/13	X	Rec'd	South Dakota Department of Health, at <a href="http://getscreened.sd.gov/registry/data/">http://getscreened.sd.gov/registry/data/</a>
	1511	9/25/13	X	Rec'd	Ovarian Cancer in South Dakota, South Dakota Department of Health, at <a href="http://getscreened.sd.gov/documents/Ovarian2008.pdf">http://getscreened.sd.gov/documents/Ovarian2008.pdf</a>
	1512				Cramer, Daniel, et al; <a href="#">Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer</a> ; Cramer, et al; Cancer Causes Control, Aug 8 2013
	1513				Terry, Kathryn L.; Karageorgi, Stalo; Shevetsov, Yurii B., et al; <i>Tubal ligation, hysterectomy, and epithelial ovarian cancer in the New England Case-Control Study</i> . International Journal of Cancer, June 12 2013
	1514				White, Kristin L., Vierkant, Robert A., Fogarty, Zachary C., Cramer, Daniel W., et al; <i>Analysis of Over 10,000 Cases Finds No Association between Previously-Reported Candidate Polymorphisms and Ovarian Cancer Outcome</i> . Cancer Epidemiol Biomarkers Prev 22(5), May 2013
	1515				Merritt, MA, M De Pari, AF Vitonis, LJ Titus, DW Cramer, and KL Terry. 2013. <i>Reproductive characteristics in relation to ovarian cancer risk by histologic pathways</i> . Hum Reprod 28(5):1406-17.



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1516				Bojesen, Stig E., et al; 2013. <a href="#">Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer</a> ; Nat Genet 45(4):371-384.
	1517				Pharoah, Paul D.P., et al; 2013. <a href="#">GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer</a> ; Nat Genet 45(4):362-370
	1518				Shen, Hui, et al; 2013. <a href="#">Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer</a> ; Nat Commun 4:1628.
	1519				Permeth-Wey, Jennifer, et al; 2013. <a href="#">Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31</a> ; Nature Commun 4:1627
	1520				Faber, Mette T., Kjaer, Susanne K., Dehlendorff, Christian, et al; <i>Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies</i> . Cancer Causes Control (2013) 24:989-1004, March 2, 2013
	1521	10/2/13	X	Demonstrative	Merritt MA, Cramer DW, Vitonis AF, Titus LF, Terry KL. <i>Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes</i> . Int J Cancer. 2013 Mar 1; 132(5):1114-24
	1522				Sieh, Weiva, et al; <a href="#">Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies</a> ; International Journal of Epidemiology 2013; 42:579-589
	1523				Cramer, Daniel, et al; <i>Duarte galactose-1-phosphate uridyl transferase genotypes are not associated with ovarian cancer risk</i> ; American Society for Reproductive Medicine, Published by Elsevier Inc. 2012
	1524	10/2/13	X	Demonstrative	Kelemen, Linda E.; Bandera, Elisa V.; Terry, Kathryn L., Cramer, Daniel W., et al; <i>Recent alcohol consumption and risk of incident ovarian carcinoma: A pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium</i> / BioMed Central Cancer 2013, 13:28 January 22, 2013
	1525	10/2/13	X	Demonstrative	Kotsopoulos, Joanne, Terry, Kathryn L.; Poole, E.M.; Rosner, B.; Murphy, M.A.; Hecht, J.L.; Crum, C.P., Missmer, S.; Cramer, Daniel W.; Tworoger, Shelley S.; 2013. <i>Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin</i> . Int J Cancer 133(3):730-9
	1526				Merritt, Melissa; Kotsopoulos, Joanne; Cramer, Daniel; Hankinson, Susan; Terry, Kathryn; Tworoger, Shelley; <i>Duarte galactose-1-phosphate uridyl transferase genotypes are not associated with ovarian cancer risk</i> / American Society for Reproductive Medicine, Published by Elsevier, inc., May 30, 2012
	1527				Merritt, Melissa; Cramer, Daniel; Vitonis, Allison; Titus, Linda; Terry, Kathryn; <i>Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes</i> / International Journal of Cancer May 2012
	1528				Pearce, Celeste; Templeman, Claire, et al; <i>Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies</i> / <a href="http://www.thelancet.com/oncology">www.thelancet.com/oncology</a> , Vol. 13, April 2012
	1529				Cramer, Daniel W., et al; <a href="#">Telomere Length and Genetic Variation in Telomere Maintenance Genes in Relation to Ovarian Cancer Risk - Dr. Cramer</a> ; American Association for Cancer Research Journal, Published OnlineFirst on 1-20-2012
	1530				Cramer, Daniel W., MD, ScD; <i>The Epidemiology of Endometrial and Ovarian Cancer by Dr. Cramer</i> ; Hematol Oncol Clin N Am 26 (2012) 1-12
	1531				Collaborative Group on Epidemiological Studies of Ovarian Cancer (CGESOC) and DW Cramer. 2012. <i>Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women and ovarian cancer from 47 epidemiological studies</i> . PLoS Med 9(4):31001200.
	1532				Collaborative Group on Epidemiological Studies of Ovarian Cancer (CGESOC) and DW Cramer. 2012. <i>Ovarian cancer and smoking: Individual participant meta-analysis including 28,114 women and ovarian cancer from 51 epidemiological studies</i> . Lancet Oncol 13(9):946-956.
	1533				Harris HR, I De Vivo, LJ Titus, AF Vitonis, JYY Wong, DW Cramer, and KL Terry. 2012. <i>Genetic variation in telomere maintenance genes in relation to ovarian cancer survival</i> . Int J Mol Epidemiol Genet 3(3):252-261.
	1534				Harris Holly R., Cramer Daniel W, Vitonis Allison F., DePari Mary, Terry, Kathryn L.; <i>Folate, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, methionine and alcohol intake in relation to ovarian cancer risk</i> / Int'l J Cancer (Accepted preprint) 2011
	1535				Merritt, Melissa A. and Cramer, W. Daniel; <i>Molecular pathogenesis of endometrial and ovarian cancer</i> . IOS Press. Cancer Biomarkers 9 (2011) 287-305, DOI 10.3233/CBM-2011-0167
	1536				Cramer, Daniel W., et al; <a href="#">Folate and ovarian cancer (Accepted Preprint) International Journal of Cancer (John Wiley &amp; Sons, Inc.) November 2011 p1-32</a>
	1537				Cramer, Daniel W., Allison Vitonis, Simone Pinheiro, John McKolanis, Raina Fichorova, Kevin Brown, Todd Hatchette, Olivera Finn; <i>Mumps and ovarian cancer: Modern interpretation of an historic association</i> / Cancer Causes Control June 2011
	1538				Pharoah, Paul D P, et al; <i>The role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing</i> / Clinical Cancer Research June 2011

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1539				Permuth-Wey, Jennifer, et al; <i>LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer</i> / Cancer Research 7(11):3896-3903.
	1540				Permuth-Wey, Jennifer, et al; <i>MicroRNA Processing and Binding Site Polymorphisms are not Replicated in the Ovarian Cancer Association Consortium</i> / Cancer Epidemiol Biomarkers Prev June 2011
	1541				Cramer, David W., Linda Titus-Ernstoff, Allison Vitonis; <i>Genital talc use and ovarian cancer: Influence of histologic type and menopausal status on strength and dose response of the association</i> / American Association for Cancer Research, 102nd Annual Meeting April 2011
	1542				Cramer, Daniel W., et al; <a href="#">Assessing Ovarian Cancer Risk When Considering Elective Oophorectomy at the Time of Hysterectomy</a> . Obstet Gynecol 117(5):1042-1050
	1543				Cramer, Daniel W., et al; <a href="#">Epidemiologic perspective on immune-surveillance in cancer</a> . ScienceDirect (Elsevier) January 2011 p1-7
	1544				Melissa A. Merritt and Daniel W. Cramer; <i>Molecular pathogenesis of endometrial and ovarian cancer</i> / IOS PRESS, CANCER BIOMARKERS 9 (2011)
	1545				Cramer, DW and AF Vitonis. 2011. <i>Thoughts on the prevention and early detection of postmenopausal ovarian cancer</i> . Menopausal Med 19(1):S1-S7
	1546				Cramer, DW and OJ Finn. 2011. <i>Epidemiologic perspective on immune-surveillance in cancer</i> . Curr Opin Immunol 23(2):265-271.
	1547				Konstantinopoulos, PA, SA Cannistra, H Fountzilas, H Culhane, K Pillay, B Rueda, D Cramer, M Seiden, M Birrer, G Coukos, L Zhang, J Quackenbush, and D Spentzos. 2011. <i>Intergrated analysis of multiple microarray datasets identified a reproducible survival predictor in ovarian cancer</i> . PLoS One 6(3):e18202
	1548				Cramer, Daniel W., et al; <a href="#">Mumps and ovarian cancer: modern interpretation of an historic association</a> . Springer Science+Business media B.V. 2010 June 18 2010, (21) p1193-1201
	1549				Cramer DW, AF Vitonis, SP Pinheiro, JR McKolanis, RN Fichorova, KE Brown, TF Hatchette, and OJ Finn. 2010. <i>Mumps and ovarian cancer: Modern interpretation of an historic association</i> . Cancer Causes Control 21(8): 1193-1201.
	1550				Bolton, KL, J Tyrer, H Son, DW Cramer, and Australian Ovarian Cancer Study Group. 2010. <i>Common variants at 19p13 are associated with susceptibility to ovarian cancer</i> . Nat Genet 42(10):880-884
	1551				Pinheiro Simone P; et al; <a href="#">Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts</a> . American journal of epidemiology (United States) Jun 1 2009, 169 (11) p1378-87
	1552				Schildkraut Joellen M; et al; <a href="#">Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer</a> . Cancer research (United States) Mar 15 2009, 69 (6) p2349-57
	1553				TwoRoger Shelley S, et al; <a href="#">Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies</a> . Cancer research (United States) Mar 1 2009, 69 (5) p1885-91
	1554				Gates Margaret A; et al; <a href="#">Flavonoid intake and ovarian cancer risk in a population-based case-control study</a> . International Journal of Cancer. Journal international du cancer (United States) Apr 15 2009, 124 (8) p1918-25
	1555				Pearce C L; et al; <a href="#">Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium</a> . British journal of cancer (England) Jan 27 2009, 100 (2) p412-20
	1556				Kotsopoulos, Joanne, Allison Vitonis, Kathryn Terry, Immaculata De Vivo, Daniel Cramer, Susan Hankinson, Shelley TwoRoger; <i>Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer</i> / Cancer Causes Control Oct. 2008
	1557				Gates Margaret A; TwoRoger Shelley S; Terry Kathryn L; Titus-Ernstoff Linda; Rosner Bernard; De Vivo Immaculata; Cramer Daniel W; Hankinson Susan E; <i>Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer</i> /Cancer Epidemiology, Biomarkers & Prevention – a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology (United States) Sept 2008
	1558				Pinheiro Simone P; et al; <a href="#">Non-genomic biomarkers of risk in ovarian cancer</a> . Disease markers (Netherlands) 2007, 23 (5-6) p355-66
	1559	9/25/13	X	Demonstrative	Cramer Daniel W; et al; <a href="#">Presence of talc in pelvic of a woman with ovarian cancer and long-term genital exposure to cosmetic talc</a> . Obstetrics and Gynecology (United States) Aug 2007, 110 (2 Pt 2) p498-501
	1560				Ye Bin; et al; <a href="#">Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence</a> . Cancer letters (Ireland) Jun 18 2007, 251 (1) p43-52
	1561				Abenham Haim A; et al; <a href="#">Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider</a> . CMAJ - Canadian Medical Association Journal (Canada) Mar 27 2007, 176 (7) p941-7

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1562				Terry, Kathryn L., Linda Titus-Ernstoff, John McKolanis, et al; <i>Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies</i> / European Journal of Cancer Prevention- the Official Journal of the European Cancer Prevention Organisation (England) Jan 2007
	1563				Terry, Kathryn L., Linda Titus-Ernstoff, John McKolanis, et al; <i>Incessant ovulation, Mucin 1 Immunity, and risk for ovarian cancer</i> / Cancer Epidemiology, Biomarkers & Prevention Jan 2007
	1564				Ye, Bin, Margarita Aponte, Yan Dai, Lily Li, Ming-Chih Ho, Allison Vitonis, Dale Edwards, Tai-Nang Huang, Daniel Cramer; <i>Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence</i> / Cancer Letters Oct 2006
	1565				Terry Kathryn L; et al; <a href="#">Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk</a> . Cancer research (United States) Jul 1 2005, 65 (13) p5974-81
	1566				Cramer Daniel W; et al; <a href="#">Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer</a> . Cancer epidemiology, biomarkers & prevention - a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (United States) May 2005, 14 (5) p1125-31
	1567				Terry Kathryn L; et al; <a href="#">Genetic variation in the progesterone receptor gene and ovarian cancer risk</a> . American journal of epidemiology (United States) Mar 1 2005, 161 (5) p442-51
	1568				Terry Kathryn L; et al; <a href="#">Blood and urine markers for ovarian cancer: a comprehensive review</a> . Disease markers (Netherlands) 2004, 20 (2) p53-70
	1569				Fairfield Kathleen M; et al; <a href="#">A prospective study of dietary lactose and ovarian cancer</a> . International Journal of Cancer. Journal international du cancer (United States) Jun 10 2004, 110 (2) p271-7
	1570				Modugno Francesmary; et al; <a href="#">Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)</a> . Cancer causes & control - CCC (Netherlands) Jun 2003, 14 (5) p439-46
	1571				Terry, Kathryn L., et al; <a href="#">Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk</a> . Cancer epidemiology, Biomarkers & Prevention Mar 2003, 12(3) p187-90
	1572				Garner Elizabeth I O; et al; <a href="#">Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer</a> . Cancer Research (United States) Jun 1 2002, 62 (11) p3058-62
	1573				Kuper H, DW Cramer, and L Titus-Ernstoff. 2002. <i>Risk of ovarian cancer in the United States in relation to anthropometric measures: Does the association depend on menopausal status?</i> . Cancer Causes Control 13(5):455-463.
	1574				Cramer D W, et al; <a href="#">Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women</a> . Int'l J Cancer Oct 1 2001, 94 (1) p128-34
	1575				Titus-Ernstoff L, et al; <a href="#">Menstrual and reproductive factors in relation to ovarian cancer risk</a> . British Journal of Cancer (Scotland) Mar 2 2001, 84 (5) p714-21
	1576				Cramer D W, et al; <a href="#">Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone</a> . Human Reproduction (Oxford, England) Oct 2000, 15 (10) p2103-7
	1577				Kuper H; Titus-Ernstoff L, et al; <a href="#">Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer</a> . Int'l J Cancer Oct 15 2000, 88 (2) p313-8
	1578				Gertig D M; Hunter D J; Cramer D W; Colditz G A; Speizer F E; Willett W C; Hankinson S E; <i>Prospective study of talc use and ovarian cancer</i> / Journal of the National Cancer Institute (United States) Feb 2000
	1579				Marchbanks P A, et al; <a href="#">Cigarette smoking and epithelial ovarian cancer by histologic type</a> . Obstetrics and gynecology (United States) Feb 2000, 95 (2) p255-60
	1580				Cramer D W, et al; <a href="#">A case-control study of galactose consumption and metabolism in relation to ovarian cancer</a> . Cancer epidemiology, biomarkers & prevention - a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (United States) Jan 2000, 9 (1) p95-101
	1581				Cramer D W; <a href="#">Perineal talc exposure and subsequent epithelial ovarian cancer: A case-control study</a> . Obstet Gynecol 94(1):160-161. July 1999.
	1582	10/1/13	X	Demonstrative	Cramer D W; Liberman R F; Titus-Ernstoff L; Welch W R; Greenberg E R; Baron J A; Harlow B L; <i>Genital talc exposure and risk of ovarian cancer</i> /Int'l J Cancer (United States) May 1999
	1583				Lu K H, et al; <a href="#">A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer</a> . Obstetrics and gynecology (United States) Jan 1999, 93 (1) p34-7
	1584				Harlow B L, et al; <a href="#">Psychotropic medication use and risk of epithelial ovarian cancer</a> . Cancer Epidemiology, Biomarkers & Prevention Aug 1998, 7 (8) p697-702

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1585				Cramer D W, et al; <a href="#">Over-the-counter analgesics and risk of ovarian cancer</a> . Lancet (England) Jan 10 1998, 351 (9096) p104-7
	1586				Muto M G, et al; <a href="#">Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls</a> . Cancer research (United States) Mar 15 1996, 56 (6) p1250-2
	1587				Cramer D W, et al; <a href="#">Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer</a> . Annals of epidemiology (United States) Jul 1995, 5 (4) p310-314
	1588				Harlow B L, et al; <a href="#">Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States)</a> . Cancer Causes & Control - CCC (England) Mar 1995, 6 (2) p130-134
	1589				Cramer D W, et al; <a href="#">Characteristics of women with a family history of ovarian cancer. II. Follicular phase hormone levels</a> . Cancer (United States) Aug 15 1994, 74 (4) p1318-22
	1590				Muto M G, et al; <a href="#">Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center</a> . Gynecologic oncology (United States) Oct 1993, 51 (1) p12-20
	1591				Harlow B L; Cramer D W; Bell D A; Welch W R; <a href="#">Perineal exposure to talc and ovarian cancer risk</a> / Obstetrics and Gynecology (United States) July 1992
	1592				Cramer D W, et al; 1991. Re: <a href="#">"A case-control study of milk drinking and ovarian cancer risk"</a> . Am J Epidemiol 134(5):454-456. Comment on: Am J. Epidemiol 132(5):871-876
	1593				Harlow B L, et al; <a href="#">The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk</a> . American Journal of Epidemiology (United States) Sep 1 1991, 134 (5) p445-53
	1594				Cramer, DW and BL Harlow. 1991. Author's response to "Progress in the nutritional epidemiology of ovary cancer". Am J Epidemiol 134(5):460-461. Comment on: Am J Epidemiol 134(5):457-459
	1595	10/2/13	X	Demonstrative	Cramer D W; <a href="#">Lactase persistence and milk consumption as determinants of ovarian cancer risk</a> . American Journal of Epidemiology (United States) Nov 1989, 130 (5) p904-10
	1596	10/2/13	X	Demonstrative	Cramer D W, et al; 1989. <a href="#">Galactose consumption and metabolism in relation to the risk of ovarian cancer</a> . Lancet 8:2(8654):66-71. July 8, 1989.
	1597				Cramer D W, et al; <a href="#">Dietary animal fat in relation to ovarian cancer risk</a> . Obstetrics and gynecology (United States) Jun 1984, 63 (6) p833-8
	1598				Cramer D W, et al; <a href="#">Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis</a> . Journal of the National Cancer Institute (United States) Oct 1983, 71 (4) p717-21
	1599				Cramer D W, et al; <a href="#">Determinants of ovarian cancer risk. I. Reproductive experiences and family history</a> . Journal of the National Cancer Institute (United States) Oct 1983, 71 (4) p711-6
	1600				Cramer D W, et al; <a href="#">Mumps, menarche, menopause, and ovarian cancer</a> . American journal of obstetrics and gynecology (United States) Sep 1 1983, 147 (1) p1-6
	1601				Cramer D W; Welch W R; Scully R E; Wojciechowski C A; <a href="#">Ovarian cancer and talc: a case-control study</a> / Cancer (United States) July 1982
	1602				Cramer D W, et al; <a href="#">Factors affecting the association of oral contraceptives and ovarian cancer</a> . New England Journal of Medicine (United States) Oct 21 1982, 307 (17) p1047-51
	1603				Cramer D W; <a href="#">Epidemiology of the gynecologic cancers</a> . Comprehensive Therapy (United States) Mar 1978, 4 (3) p9-17
	1604				Cramer D W, et al; <a href="#">Incidence and histopathology of malignancies of the female genital organs in the United States</a> . American Journal of Obstetrics and Gynecology (United States) Feb 15 1974, 118 (4) p443-60
	1605				Medical records from Avera McKennan Hospital; DBerg-AveraMH-MD-000001-124
	1606				Billing records from Avera McKennan Hospital; DBerg-AveraMH-BD-000001-4
	1607				Medical records from Brigham Medical Group; DBerg-BrighamMG-MD-000001-2
	1608				Medical records from Christopher Hurley, M.D.; DBerg-CHurley-000001-3
	1609				Medical records from Express Scripts; DBerg-ES-000001
	1610				Medical records from LCM Pathologists; DBerg-LCMPathologists-000001
	1611				Medical records from McGreevy Clinic; DBerg-McGreevyC-MD-000001-71
	1612				Billing records from McGreevy Clinic; DBerg-McGreevyC-BD-000001-6
	1613				Medical records from Medco Health Solutions; DBerg-MHS-000001-8
	1614				Medical records from Neurology Associates, P.C.; DBerg-NeuroAssoc-MD-000001-67
	1615				Billing records from Neurology Associates, P.C.; DBerg-NeuroAssoc-BD-000001-8
	1616				Medical records from Physician's Laboratory, Ltd.; DBerg-PhysLab-MD-000001-3



PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1617				Billing records from Physician's Laboratory, Ltd.; DBerg-PhysLab-BD-000001-3
	1618				Medical records from Sanford Clinic Adult Medicine; DBerg-SCAM-MD-000001-45
	1619				Medical records from Sanford Clinic Behavioral Health; DBerg-SCBH-000001-17
	1620				Medical records from Sanford Clinic Family Medicine; DBerg-SCFM-SD-MD-000001-8
	1621				Medical records from Sanford Clinic Fetal Medicine; DBerg-SCFMF-000001-232
	1622				Medical records from Sanford Clinic Women's Health; DBerg-SCWH-MD-000001-330
	1623				Medical records from Sanford USD Medical Center; DBerg-SanUSDMC-MD-000001-918
	1624				Billing records from Sanford USD Medical Center; DBerg-SanUSDMC-BD-000001-45
	1625				Medical records from Sioux Falls Surgical Center; DBerg-SFSC-MD-000001-31
	1626				Billing records from Sioux Falls Surgical Center; DBerg-SFSC-BD-000001
	1627				Medical records from Sioux Falls VA Medical Center; DBerg-SF-VAMC-MD-000001-207
	1628				Medical records from Timothy Walker, MD; DBerg-TWalker-000001-7
	1629				Medical records from Walgreen Company; DBerg-WC-000001-51
	1630				Employment records from Sioux Falls VA Medical Center; DBerg-SFVAMC-HR-000001-531
	1631				August 23, 1982 letter from Dr. Iaan T.T. Higgins, Professor of Epidemiology, the University of Michigan, to James McNerny critiquing Dr. Cramer's literature (JNJ 000029635 - JNJ 000029637) **
	1632				Comment on paper by D.W. Cramer, W.R. Welch, R.E. Scully and C.A. Wojciechowski titled "Ovarian Cancer and Talc" published in Cancer 50:372-376, 1982, prepared by William E. Smith, M.D. (JNJ 000036463 - JNJ 000036476) **
	1633				March 15, 1983 letter from Dr. William E. Smith, Farleigh Dickinson University, to Dr. Bruce Semple with comments on Dr. Cramer's paper titled "Ovarian Cancer and Talc" (JNJ 000036458 - JNJ 000036462) **
	1634				September 10, 1982 letter from Dr. Francis J.C. Roe with comments and paper by P. N. Lee on Dr. Cramer's paper "Ovarian Cancer and Talc: A Case-Control Study" (JNJ 000021003 - JNJ 000021005) **
	1635				Critiques of NTP Technical Report on the Toxicology and Cacinogenesis Studies of Talc in F344/N Rats and B6C3F <sub>1</sub> Mice and Perineal Exposure to Talc and Ovarian Cancer prepared by Biomedical and Environmental Consultants, Inc. (JNJ 000009228- JNJ 000009455) **
	1636				Biological Effects of Cosmetic Talc: A Literature Review by Alfred P. Wehner, November 1993 (JNJ 000009643- JNJ 000009772) **
	1637				March 6, 1997 memo criticizing Cook study regarding talc and use of deodorant sprays (JNJ 000015539- JNJ 000015540) **
	1638				March 15, 1997 letter from Dr. Samuel Shapiro and A Critique of paper by LS Cook, ML Kamb, and NN Weiss titled "Perineal powder exposure and the risk of ovarian cancer." Am J Epidemiol 1997; 145:459-65 (JNJ 000010515- JNJ 000010520) **
	1639				Comments on Cook LS, Kamb JL, Weiss NSW: Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 145:459-65. (JNJ 000010522 - JNJ 000010525) **
	1640				March 10, 1997 letter from Institute for Evaluating Health Risks to Dr. Rosanne B. McTyre addressing the article "Perineal powder exposure and the risk of ovarian cancer" by LS Cook, et al (JNJ 000010521) **
	1641				July 17, 1999 letter from Dr. Alfred P. Wehner to William Ashton regarding Dr. Daniel Cramer's 1999 article (JNJ 000011956- JNJ 000011960) **
	1642				Review and Critique of Epidemiology Studies of Talc and its Relationship to Ovarian Cancer by Judith K. Jones, M.D., Ph.D. dated November 27, 2000 (JNJ 000002412- JNJ 000002438) **
	1643	10/1/13	X	Demonstrative	Rothman, et al; <i>Interpretation of Epidemiologic Studies on Talc and Ovarian Cancer</i> , November 28, 2000 (JNJ 000001465- JNJ 000001475) **
	1644				September 21, 1982 letter from Dr. Iaan T.T. Higgins, Professor of Epidemiology, the University of Michigan, to James McNerny regarding article titled "Ovarian Cancer and Talc: A Case-Control Study" by Dr. DW Cramer, et al. (JNJ 000036481 - JNJ 000036483) **

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1645				Proc. Microscopy and Microanalysis 2013, Ed. J. Shields, et al., Indianapolis, IN, Cambridge University Press (2013).
	1646				Industrial Mineral Uses, available at <a href="http://www.peterharben.com/industrial_mineral_uses.htm">www.peterharben.com/industrial_mineral_uses.htm</a> .
	1647				Huncharek M, Muscat J. <i>Perineal talc use and ovarian cancer risk: A case-study of scientific standards in environmental epidemiology</i> . Eur J Cancer Prev 20(6):501-507, 2011.
	1648				Huncharek M, Muscat J, Kupelnick B. Cancer risk associated with occupational exposure to talc: Results of ameta-analysis. (in preparation)
	1649				Muscat J, Huncharek M, Kupelnick B. Perineal talc use and ovarian cancer risk: A meta-analytic evaluation of the dose-response relationship. (in preparation).
	1650				Huncharek M, Kupelnick B. Perineal cosmetic talc use and the risk of epithelial ovarian cancer: Results of ameta-analysis. Presented at the International Congress of Epidemiology, Montreal, Canada, August 18-22, 2002  (Library unable to locate as cited)
	1651				Huncharek M, Muscat J. Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: A meta-analysis of nine observational studies, Ovarian Cancer. Prevention and Deflection of the Disease and It's Recurrence, University of Pittsburgh Cancer Institute, Herberman Conference Center, Pittsburgh, PA, Oct. 24-25, 2005.
	1652				Huncharek M, Muscat J. Talc and ovarian cancer. A critical review. Prepared for Crowell and Moring, Washington, DC, July, 2005.
	1653				Huncharek M, Muscat J. Risk of ovarian cancer associated with talc dusting of contraceptive diaphragms. Prepared for Crowell and Moring, Washington, DC, September, 2005.
	1654				Huncharek M, Muscat J. Response to citizens "Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products." Prepared for Johnson and Johnson Consumer Products Worldwide, Skillman, NJ, November 19, 2008
	1655				SEM images and spectra referenced in Expert Witness Report of Elaine Schumacher and Joseph R. Swider entitled <i>Identification of Talc Particles in Tissue Samples</i>
	1656				<a href="http://www.talclitigationgroup.com">www.talclitigationgroup.com</a> , attached as Exhibit 4 to Deposition of Dr. Godleski
	1657				Anatomical Diagrams, attached as Exhibits 6 & 7 to Deposition of Dr. Godleski
	1658				SEM images and spectra, attached as Exhibits 9 & 10 to Deposition of Dr. Godleski
	1659				Paraffin Sections Protocol for SEM, included in Exhibit 11 to Deposition of Dr. Godleski
	1660				Questionnaires referenced in Deposition of Dr. Daniel Cramer
	1661				2000 Internal Revenue Service Wage and Income Transcript
	1662				2001 Internal Revenue Service Wage and Income Transcript
	1663				2002 Internal Revenue Service Wage and Income Transcript
	1664				2003 Internal Revenue Service Wage and Income Transcript
	1665				2004 Internal Revenue Service Wage and Income Transcript
	1666				2005 Internal Revenue Service Wage and Income Transcript
	1667				2007 Tax Return Transcript
	1668				2008 Tax Return Transcript
	1669				2009 Tax Return Transcript
	1670				2010 W-2 Wage and Tax Statement
	1671				Report of Opinion on the Relationship between Ovarian Cancer and Cosmetic Talc Powder Use: Causality and Relevance to the Case of Ms. Deane Berg Expert by Daniel W. Cramer, M.D., ScD.  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Cramer's report in this exhibit list, J&J in no way acknowledges or accepts his qualifications or the relevance and reliability of his opinions. J&J has specifically challenged the qualifications, relevance, and reliability of Dr. Cramer and his opinions in pretrial <i>Daubert</i> briefing, and J&J has reasserted these challenges in its pretrial motion in limine filed contemporaneously with this exhibit list.

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1672				Economic Loss Appraisal for Deane R. Berg prepared by Ralph J. Brown, PhD  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Brown's report in this exhibit list, J&J in no way acknowledges or accepts his qualifications or the relevance and reliability of his opinions.
	1673				Expert Witness Report of John J. Godleski, M.D.  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Godleski's report in this exhibit list, J&J in no way acknowledges or accepts his qualifications or the relevance and reliability of his opinions. J&J has specifically challenged the qualifications, relevance, and reliability of Dr. Godleski and his opinions in pretrial <i>Daubert</i> briefing, and J&J has reasserted these challenges in its pretrial motion in limine filed contemporaneously with this exhibit list.
	1674				Expert Witness Report of Thomas S. Pittman, PhD, DFTCB  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Pittman's report in this exhibit list, J&J in no way acknowledges or accepts his qualifications or the relevance and reliability of his opinions.
	1675				Human Factors Analysis Report of David R. Lenorovitz, PhD, CPE and Edward W. Karnes, PhD, CHFP  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Karnes' and Lenorovitz's report in this exhibit list, J&J in no way acknowledges or accepts their qualifications or the relevance and reliability of their opinions. J&J has specifically challenged the qualifications, relevance, and reliability of these experts and their opinions in pretrial <i>Daubert</i> briefing, and J&J has reasserted these challenges in its pretrial motion in limine filed contemporaneously with this exhibit list.
	1676				Opinion on Relationships between Immunotoxicology, Cosmetic Talc Use and Ovarian Cancer: Biological Plausibility Relevant to the Case of Ms. Deane Berg by Gary J. Rosenthal, PhD, DABT  J&J lists Plaintiff's retained experts' reports solely for purposes of cross examination. By identifying Dr. Rosenthal's report in this exhibit list, J&J in no way acknowledges or accepts his qualifications or the relevance and reliability of his opinions. J&J has specifically challenged the qualifications, relevance, and reliability of Dr. Rosenthal and his opinions in pretrial <i>Daubert</i> briefing, and J&J has reasserted these challenges in its pretrial motion in limine filed contemporaneously with this exhibit list.
	1677	9/25/13	X	Rec'd	Sanford Health Ovarian Cancer Information (including information designated in Plaintiff's supplemental exhibit list)
	1678	10/2/13	X	Demonstrative	Poole, Elizabeth M.; Merritt, Melissa A.; Cramer, Daniel W., Terry, Kathryn L.; et al; <i>Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness / Cancer Epidemiol Biomarkers Prev</i> ; 22(3) March 2013.
	1679	9/25/13	X	Rec'd	WHMIS/Health Canada Information pertaining to talc, including associated background information from WHMIS & Health Canada
	1680				Shushan A, et al., Human menopausal gonadotropin and the risk of epithelial ovarian cancer, <i>Fertil Steril.</i> , 1996;65(1):13-18.
	1681	9/25/13	X	Rec'd	WHMIS/Health Canada Classification
	1682	9/26/13	X	Demonstrative	Photo of ovarian tissue from slide SFS06-37460-1A
	1683	9/26/13	X	Demonstrative	Photo of portion of the lumen of the fallopian tube
	1684	9/30/13	X	Rec'd	Sanford USM Medical Center pathology report
	1685	9/30/13	X	Demonstrative	Photos of process and slides
	1686	9/30/13	X	Demonstrative	Powerpoint slides
	1687	10/1/13	X	Demonstrative	Dr. Muscat powerpoint slides
	1688	10/1/13	X	Demonstrative	Chlorination, Chlorination By-products, and Cancer: A Meta-analysis
	1689	10/1/13	X	Demonstrative	Coffee and Cancer of the Pancreas
	1690	10/1/13	X	Demonstrative	Long-term use of cellular phones and brain tumours: increased risk associated with use for $\geq 10$ years
	1691	10/1/13	X	Demonstrative	Experimental Production of Carcinoma with Cigarette Tar IV. Successful Experiments with Rabbits

PLF. NO.	DEF. NO.	DATE OFFERED	MARKED	ADMITTED	DESCRIPTION OF EXHIBITS
	1692	10/1/13	X	Demonstrative	Down syndrome, paternal age, maternal age and birth order
	1693	10/1/13	X	Demonstrative	Update of the Follow-Up of Mortality and Cancer Incidence among European Workers Employed in the Vinyl Chloride Industry
	1694	10/1/13	X	Demonstrative	Cigarette smoking and lung cancer- relative risk estimates for the major histological types from a pooled analysis of case-control studies
	1695	10/1/13	X	Demonstrative	American Health Foundation Executive Summary
	1696	10/1/13	X	Demonstrative	Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942-72; update of cancer mortality to 31 December 1995
	1697	10/1/13	X	Demonstrative	Confounding and Effect Measure Modification
	1698	10/1/13	X	Demonstrative	Electric Blanket Use and Breast Cancer in the Nurses' Health Study
	1699	10/1/13	X	Demonstrative	IGCS Abstract 10/13/12
	1700	10/1/13	X	Demonstrative	Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma
	1701	10/1/13	X	Demonstrative	CTFA review of Nominations for Listing in the 10 <sup>th</sup> Report on Carcinogens
	1702	10/1/13	X	Demonstrative	Mini Review Outdoor Air Pollution and Lung Cancer: Recent Epidemiologic Evidence
	1703	10/1/13	X	Demonstrative	SEER Stat Fact Sheets: Ovary
	1704	10/1/13	X	Demonstrative	Red and Processed Meat and Colorectal Cancer Incidence: Meta-Analysis of Prospective Studies
	1705	10/2/13	X	Demonstrative	Dr. Hopkins powerpoint slides

**\*\* Denotes exhibit subject to Stipulated Protective Order entered in this case.**